Affiliations
Department of Medicine, Division of General Internal Medicine, University of Michigan
VA Ann Arbor Healthcare System, Ann Arbor, Michigan
Given name(s)
Lauren
Family name
Heidemann
Degrees
MD

The Authors Reply: “Cost and Utility of Thrombophilia Testing”

Article Type
Changed
Fri, 12/14/2018 - 08:05

We thank Dr. Berse and colleagues for their correspondence about our paper.1,2 We are pleased they agreed with our conclusion: Thrombophilia testing has limited clinical utility in most inpatient settings.

Berse and colleagues critiqued details of our methodology in calculating payer cost, including how we estimated the number of Medicare claims for thrombophilia testing. We estimated that there were at least 280,000 Medicare claims in 2014 using CodeMap® (Wheaton Partners, LLC, Schaumburg, IL), a dataset of utilization data from the Physician Supplier Procedure Summary Master File from all Medicare Part B carriers.3 This estimate was similar to that reported in a previous publication.4

Berse and colleagues generated a lower cost estimate of $405 for 11 of the 13 thrombophilia tests referenced in our paper (excluding factor V and methylenetetrahydrofolate reductase mutations) by using the average Medicare payment.2 However, private insurance companies or self-paying patients often pay multiples of Medicare reimbursement. Our institutional data suggest that the average reimbursement across all payors not based on a diagnosis-related group for 12 of these 13 tests is $1,327 (Table). Importantly, these expenses do not factor in costs related to increased premiums for health, disability, and life insurance that may occur due to an inappropriately ordered, positive thrombophilia test. Nor, for that matter, do they include the psychological stress of the patient that may result from a positive genetic test.

Thus, regardless of the precise estimates, even a conservative estimate of 33 to 80 million dollars of unnecessary spending is far too much. Rather, it is a perfect example of “Things We Do for No Reason.”

Disclosure

Nothing to report.

References

1. Petrilli CM, Mack M, Petrilli JJ, Hickner A, Saint S, Chopra V. Understanding the role of physician attire on patient perceptions: a systematic review of the literature--targeting attire to improve likelihood of rapport (TAILOR) investigators. BMJ Open. 2015;5(1):e006578. DOI:10.1136/bmjopen-2014-006578. PubMed
2. Berse B, Lynch JA, Bowen S, Grosse SD. In Reference to: “Cost and Utility of Thrombophilia Testing.” J Hosp Med. 2017;12(9):783. 
3. CodeMap® https://www.codemap.com/. Accessed March 2, 2017.
4. Somma J, Sussman, II, Rand JH. An evaluation of thrombophilia screening in an urban tertiary care medical center: A “real world” experience. Am J Clin Pathol. 2006;126(1):120-7. DOI:10.1309/KV06-32LJ-8EDM-EWQT. PubMed

Article PDF
Issue
Journal of Hospital Medicine 12 (9)
Publications
Topics
Page Number
784
Sections
Article PDF
Article PDF

We thank Dr. Berse and colleagues for their correspondence about our paper.1,2 We are pleased they agreed with our conclusion: Thrombophilia testing has limited clinical utility in most inpatient settings.

Berse and colleagues critiqued details of our methodology in calculating payer cost, including how we estimated the number of Medicare claims for thrombophilia testing. We estimated that there were at least 280,000 Medicare claims in 2014 using CodeMap® (Wheaton Partners, LLC, Schaumburg, IL), a dataset of utilization data from the Physician Supplier Procedure Summary Master File from all Medicare Part B carriers.3 This estimate was similar to that reported in a previous publication.4

Berse and colleagues generated a lower cost estimate of $405 for 11 of the 13 thrombophilia tests referenced in our paper (excluding factor V and methylenetetrahydrofolate reductase mutations) by using the average Medicare payment.2 However, private insurance companies or self-paying patients often pay multiples of Medicare reimbursement. Our institutional data suggest that the average reimbursement across all payors not based on a diagnosis-related group for 12 of these 13 tests is $1,327 (Table). Importantly, these expenses do not factor in costs related to increased premiums for health, disability, and life insurance that may occur due to an inappropriately ordered, positive thrombophilia test. Nor, for that matter, do they include the psychological stress of the patient that may result from a positive genetic test.

Thus, regardless of the precise estimates, even a conservative estimate of 33 to 80 million dollars of unnecessary spending is far too much. Rather, it is a perfect example of “Things We Do for No Reason.”

Disclosure

Nothing to report.

We thank Dr. Berse and colleagues for their correspondence about our paper.1,2 We are pleased they agreed with our conclusion: Thrombophilia testing has limited clinical utility in most inpatient settings.

Berse and colleagues critiqued details of our methodology in calculating payer cost, including how we estimated the number of Medicare claims for thrombophilia testing. We estimated that there were at least 280,000 Medicare claims in 2014 using CodeMap® (Wheaton Partners, LLC, Schaumburg, IL), a dataset of utilization data from the Physician Supplier Procedure Summary Master File from all Medicare Part B carriers.3 This estimate was similar to that reported in a previous publication.4

Berse and colleagues generated a lower cost estimate of $405 for 11 of the 13 thrombophilia tests referenced in our paper (excluding factor V and methylenetetrahydrofolate reductase mutations) by using the average Medicare payment.2 However, private insurance companies or self-paying patients often pay multiples of Medicare reimbursement. Our institutional data suggest that the average reimbursement across all payors not based on a diagnosis-related group for 12 of these 13 tests is $1,327 (Table). Importantly, these expenses do not factor in costs related to increased premiums for health, disability, and life insurance that may occur due to an inappropriately ordered, positive thrombophilia test. Nor, for that matter, do they include the psychological stress of the patient that may result from a positive genetic test.

Thus, regardless of the precise estimates, even a conservative estimate of 33 to 80 million dollars of unnecessary spending is far too much. Rather, it is a perfect example of “Things We Do for No Reason.”

Disclosure

Nothing to report.

References

1. Petrilli CM, Mack M, Petrilli JJ, Hickner A, Saint S, Chopra V. Understanding the role of physician attire on patient perceptions: a systematic review of the literature--targeting attire to improve likelihood of rapport (TAILOR) investigators. BMJ Open. 2015;5(1):e006578. DOI:10.1136/bmjopen-2014-006578. PubMed
2. Berse B, Lynch JA, Bowen S, Grosse SD. In Reference to: “Cost and Utility of Thrombophilia Testing.” J Hosp Med. 2017;12(9):783. 
3. CodeMap® https://www.codemap.com/. Accessed March 2, 2017.
4. Somma J, Sussman, II, Rand JH. An evaluation of thrombophilia screening in an urban tertiary care medical center: A “real world” experience. Am J Clin Pathol. 2006;126(1):120-7. DOI:10.1309/KV06-32LJ-8EDM-EWQT. PubMed

References

1. Petrilli CM, Mack M, Petrilli JJ, Hickner A, Saint S, Chopra V. Understanding the role of physician attire on patient perceptions: a systematic review of the literature--targeting attire to improve likelihood of rapport (TAILOR) investigators. BMJ Open. 2015;5(1):e006578. DOI:10.1136/bmjopen-2014-006578. PubMed
2. Berse B, Lynch JA, Bowen S, Grosse SD. In Reference to: “Cost and Utility of Thrombophilia Testing.” J Hosp Med. 2017;12(9):783. 
3. CodeMap® https://www.codemap.com/. Accessed March 2, 2017.
4. Somma J, Sussman, II, Rand JH. An evaluation of thrombophilia screening in an urban tertiary care medical center: A “real world” experience. Am J Clin Pathol. 2006;126(1):120-7. DOI:10.1309/KV06-32LJ-8EDM-EWQT. PubMed

Issue
Journal of Hospital Medicine 12 (9)
Issue
Journal of Hospital Medicine 12 (9)
Page Number
784
Page Number
784
Publications
Publications
Topics
Article Type
Sections
Article Source

© 2017 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Christopher Petrilli, MD, Michigan Medicine,1500 E. Medical Center Drive, Ann Arbor, MI 48105. Telephone: 734-936-5582; Fax: 734-647-9443; E-mail: cpetrill@med.umich.edu
Content Gating
Open Access (article Unlocked/Open Access)
Alternative CME
Disqus Comments
Default
Use ProPublica
Article PDF Media

A Contemporary Assessment of Mechanical Complication Rates and Trainee Perceptions of Central Venous Catheter Insertion

Article Type
Changed
Tue, 08/22/2017 - 04:56
Display Headline
A Contemporary Assessment of Mechanical Complication Rates and Trainee Perceptions of Central Venous Catheter Insertion

Central venous catheter (CVC) placement is commonly performed in emergency and critical care settings for parenteral access, central monitoring, and hemodialysis. Although potentially lifesaving CVC insertion is associated with immediate risks including injury to nerves, vessels, and lungs.1-3 These “insertion-related complications” are of particular interest for several reasons. First, the frequency of such complications varies widely, with published rates between 1.4% and 33.2%.2-7 Reasons for such variation include differences in study definitions of complications (eg, pneumothorax and tip position),2,5 setting of CVC placement (eg, intensive care unit [ICU] vs emergency room), timing of placement (eg, elective vs emergent), differences in technique, and type of operator (eg, experienced vs learner). Thus, the precise incidence of such events in modern-day training settings with use of ultrasound guidance remains uncertain. Second, mechanical complications might be preventable with adequate training and supervision. Indeed, studies using simulation-based mastery techniques have demonstrated a reduction in rates of complications following intensive training.8 Finally, understanding risk factors associated with insertion complications might inform preventative strategies and improve patient safety.9-11

Few studies to date have examined trainees’ perceptions on CVC training, experience, supervision, and ability to recognize and prevent mechanical complications. While research investigating effects of simulation training has accumulated, most focus on successful completion of the procedure or individual procedural steps with little emphasis on operator perceptions.12-14 In addition, while multiple studies have shown that unsuccessful line attempts are a risk factor for CVC complications,3,4,7,15 there is very little known about trainee behavior and perceptions regarding unsuccessful line placement. CVC simulation trainings often assume successful completion of the procedure and do not address the crucial postprocedure steps that should be undertaken if a procedure is unsuccessful. For these reasons, we developed a survey to specifically examine trainee experience with CVC placement, supervision, postprocedural behavior, and attitudes regarding unsuccessful line placement.

Therefore, we designed a study with 2 specific goals: The first is to perform a contemporary analysis of CVC mechanical complication rate at an academic teaching institution and identify potential risk factors associated with these complications. Second, we sought to determine trainee perceptions regarding CVC complication experience, prevention, procedural supervision, and perceptions surrounding unsuccessful line placement.

METHODS

Design and Setting

We conducted a single-center retrospective review of nontunneled acute CVC procedures between June 1, 2014, and May 1, 2015, at the University of Michigan Health System (UMHS). UMHS is a tertiary care referral center with over 900 inpatient beds, including 99 ICU beds.

All residents in internal medicine, surgery, anesthesia, and emergency medicine receive mandatory education in CVC placement that includes an online training module and simulation-based training with competency assessment. Use of real-time ultrasound guidance is considered the standard of care for CVC placement.

Data Collection

Inpatient procedure notes were electronically searched for terms indicating CVC placement. This was performed by using our hospital’s Data Office for Clinical and Translational Research using the Electronic Medical Record Search Engine tool. Please see the supplemental materials for the full list of search terms. We electronically extracted data, including date of procedure, gender, and most recent body mass index (BMI), within 1 year prior to note. Acute Physiology and Chronic Health Evaluation III (APACHE III) data are tracked for all patients on admission to ICU; this was collected when available. Charts were then manually reviewed to collect additional data, including international normalized ratio (INR), platelet count, lactate level on the day of CVC placement, anticoagulant use (actively prescribed coumadin, therapeutic enoxaparin, therapeutic unfractionated heparin, or direct oral anticoagulant), ventilator or noninvasive positive pressure ventilation (NIPPV) at time of CVC placement, and vasopressor requirement within 24 hours of CVC placement. The procedure note was reviewed to gather information about site of CVC placement, size and type of catheter, number of attempts, procedural success, training level of the operator, and attending presence. Small bore CVCs were defined as 7 French (Fr) or lower. Large bore CVCs were defined as >7 Fr; this includes dialysis catheters, Cordis catheters (Cordis, Fremont, CA), and cooling catheters. The times of the procedure note and postprocedure chest x-ray (CXR) were recorded, including whether the CVC was placed on a weekend (Friday 7 pm to Sunday at midnight) or weekday.

 

 

Primary Outcome

The primary outcome was the rate of severe mechanical complications related to CVC placement. Similar to prior studies,2 we defined severe mechanical complications as arterial placement of dilator or catheter, hemothorax, pneumothorax, cerebral ischemia, patient death (related to procedure), significant hematoma, or vascular injury (defined as complication requiring expert consultation or blood product transfusion). We did not require a lower limit on blood transfusion. We considered pneumothorax a complication regardless of whether chest tube intervention was performed, as pneumothorax subjects the patient to additional tests (eg, serial CXRs) and sometimes symptoms (shortness of breath, pain, anxiety) regardless of whether or not a chest tube was required. Complications were confirmed by a direct review of procedure notes, progress notes, discharge summaries, and imaging studies.

Trainee Survey

A survey was electronically disseminated to all internal medicine and medicine-pediatric residents to inquire about CVC experiences, including time spent in the medical ICU, number of CVCs performed, postprocedure behavior for both failed and successful CVCs, and supervision experience and attitudes. Please see supplemental materials for full survey contents.

Statistical Methods

Descriptive statistics (percentage) were used to summarize data. Continuous and categorical variables were compared using Student t tests and chi-square tests, respectively. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).

Ethical and Regulatory Oversight

The study was deemed exempt by the University of Michigan Institutional Review Board (HUM00100549) as data collection was part of a quality improvement effort.

RESULTS

Demographics and Characteristics of Device Insertion

Between June 1, 2014, and May 1, 2015, 730 CVC procedure notes were reviewed (Table 1). The mean age of the study population was 58.9 years, and 41.6% (n = 304) were female. BMI data were available in 400 patients without complications and 5 patients with complications; the average BMI was 31.5 kg/m2. The APACHE III score was available for 442 patients without complications and 10 patients with complications; the average score was 86 (range 19-200). Most of the CVCs placed (n= 504, 69%) were small bore (<7 Fr). The majority of catheters were placed in the internal jugular (IJ) position (n = 525, 71.9%), followed by femoral (n = 144, 19.7%), subclavian (N = 57, 7.8%), and undocumented (n = 4, 0.6%). Ninety-six percent (n = 699) of CVCs were successfully placed. Seventy-six percent (n = 558) of procedure notes included documentation of the number of CVC attempts; of these, 85% documented 2 or fewer attempts. The majority of CVCs were placed by residents (n = 537, 73.9%), followed by fellows (N = 127, 17.5%) and attendings (n = 27, 3.7%). Attending supervision for all or key portions of CVC placement occurred 34.7% (n = 244) of the time overall and was lower for internal medicine trainees (n = 98/463, 21.2%) compared with surgical trainees (n = 73/127, 57.4%) or emergency medicine trainees (n = 62/96, 64.6%; P < 0.001). All successful IJ and subclavian CVCs except for 2 insertions (0.3%) had a postprocedure CXR. A minority of notes documented pressure transduction (4.5%) or blood gas analysis (0.2%) to confirm venous placement.

Lab data, information on utilization of anticoagulation, vasopressors, ventilation, and information on the use of transduction and blood gas data were collected for the first 410 uncomplicated patients and all patients that experienced complications (Table 2). The mean INR was 1.5 (range 0.9-9.7), mean platelets 180 K/uL (range 9-816 K/uL), and mean lactate 2.9 mmol/L (range 0.4-16 mmol/L). Twenty-one percent (n = 86) of patients were systemically anticoagulated at the time of CVC placement, 59% (n = 251) received vasopressors within 24 hours of CVC placement, and 63% (n = 265) were mechanically ventilated (Table 2).

Mechanical Complications

The mechanical complications identified included pneumothorax (n = 5), bleeding requiring transfusion (n = 3), vascular injury requiring expert consultation or intervention (n = 3), stroke (n = 1), and death (n = 2). Vascular injuries included 1 neck hematoma with superinfection requiring antibiotics, 1 neck hematoma requiring otolaryngology and vascular surgery consultation, and 1 venous dissection of IJ vein requiring vascular surgery consultation. None of these cases required operative intervention. The stroke was caused by inadvertent CVC placement into the carotid artery. One patient experienced tension pneumothorax and died due to this complication; this death occurred after 3 failed left subclavian CVC attempts and an ultimately successful CVC placement into left IJ vein. Another death occurred immediately following unsuccessful Cordis placement. As no autopsy was performed, it is impossible to know if the cause of death was the line placement. However, it would be prudent to consider this as a CVC complication given the temporal relationship to line placement. Thus, the total number of patients who experienced severe mechanical complications was 14 out of 730 (1.92%).

 

 

Risk Factors for Mechanical Complications

Certain patient factors were more commonly associated with complications. For example, BMI was significantly lower in the group that experienced complications vs those that did not (25.7 vs 31.0 kg/m2, P = 0.001). No other associations between demographic factors, including age (61.4 years vs 58.9 years, P = 0.57) or sex (57.1% male vs 41.3% female, P = 0.24), or admission APACHE III score (96 vs 86, P = 0.397) were noted. The mean INR, platelets, and lactate did not differ between the 2 groups. There was no difference between the use of vasopressors. Ventilator use (including endotracheal tube or NIPPV) was found to be significantly higher in the group that experienced mechanical complications (78.5% vs 65.9%, P = 0.001). Anticoagulation use was also associated with mechanical complications (28.6% vs 20.6%, P = 0.05); 3 patients on anticoagulation experienced significant hematomas. Mechanical complications were more common with subclavian location (21.4% vs 7.8%, P = 0.001); in all 3 cases involving subclavian CVC placement, the complication experienced was pneumothorax. The number of attempts significantly differed between the 2 groups, with an average of 1.5 attempts in the group without complications and 2.2 attempts in the group that experienced complications (P = 0.02). Additionally, rates of successful placement were lower among patients who experienced complications (78.6% vs 95.7%, P = 0.001).

With respect to operator characteristics, no significant difference between the levels of training was noted among those who experienced complications vs those who did not. Attending supervision was more frequent for the group that experienced complications (61.5% vs 34.2%, P = 0.04). There was no significant difference in complication rate according to the first vs the second half of the academic year (0.4% vs 0.3% per month, P = 0.30) or CVC placement during the day vs night (1.9% vs 2.0%, P = 0.97). A trend toward more complications in CVCs placed over the weekend compared to a weekday was observed (2.80% vs 1.23%, P = 0.125).

Unsuccessful CVCs

There were 30 documented unsuccessful CVC procedures, representing 4.1% of all procedures. Of these, 3 procedures had complications; these included 2 pneumothoraxes (1 leading to death) and 1 unexplained death. Twenty-four of the unsuccessful CVC attempts were in either the subclavian or IJ location; of these, 5 (21%) did not have a postprocedure CXR obtained.

Survey Results

The survey was completed by 103 out of 166 internal medicine residents (62% response rate). Of these, 55% (n = 57) reported having performed 5 or more CVCs, and 14% (n = 14) had performed more than 15 CVCs.

All respondents who had performed at least 1 CVC (n = 80) were asked about their perceptions regarding attending supervision. Eighty-one percent (n = 65/80) responded that they have never been directly supervised by an attending during CVC placement, while 16% (n = 13/80) reported being supervised less than 25% of the time. Most (n = 53/75, 71%) did not feel that attending supervision affected their performance, while 21% (n = 16/75) felt it affected performance negatively, and only 8% (n = 6/75) stated it affected performance positively. Nineteen percent (n = 15/80) indicated that they prefer more supervision by attendings, while 35% (n = 28/80) did not wish for more attending supervision, and 46% (n = 37/80) were indifferent.

All respondents who had performed at least 1 CVC were asked about postprocedure protocols. The vast majority (n = 77/80, 95%) reported documenting a postprocedure note more than 75% of the time after a successful procedure; in contrast, only 38% (n = 30/80) of those who had failed a CVC placement reported documenting a procedure note more than 75% of the time (Figure 1). Only 35% (n = 21/60) of respondents reported routinely (100% of the time) ordering a CXR after a failed chest CVC attempt (Figure 2), and 47% (n = 28/60) only ordered a CXR if they were concerned there was a complication. Most (69%, n = 55/80) felt it was important to order a CXR after a failed chest CVC placement, while 6% (n = 5/80) did not feel it was important, and 25% (n = 20/80) did not know or were indifferent.

DISCUSSION

We performed a contemporary analysis of CVC placement at an academic tertiary care center and observed a rate of severe mechanical complications of 1.9%. This rate is within previously described acceptable thresholds.16 Our study adds to the literature by identifying several important risk factors for development of mechanical complications. We confirm many risk factors that have been noted historically, such as subclavian line location,2,3 attending supervision,3 low BMI,4 number of CVC attempts, and unsuccessful CVC placement.3,4,7,15 We identified several unique risk factors, including systemic anticoagulation as well as ventilator use. Lastly, we identified unexpected deficits in trainee knowledge surrounding management of failed CVCs and negative attitudes regarding attending supervision.

 

 

Most existing literature evaluated risk factors for CVC complication prior to routine ultrasound use;3-5,7,15 surprisingly, it appears that severe mechanical complications do not differ dramatically in the real-time ultrasound era. Eisen et al.3 prospectively studied CVC placement at an academic medical center and found a severe mechanical complication rate (as defined in our paper) of 1.9% due to pneumothorax (1.3%), hemothorax (0.3%), and death (0.3%).We would expect the number of complications to decrease in the postultrasound era, and indeed it appears that pneumothoraces have decreased likely due to ultrasound guidance and decrease in subclavian location. However, in contrast, rates of significant hematomas and bleeding are higher in our study. Although we are unable to state why this may be the case, increasing use of anticoagulation in the general population might explain this finding.17 For instance, of the 6 patients who experienced hematomas or vascular injuries in our study, 3 were on anticoagulation at the time of CVC placement.

Interestingly, time of academic year of CVC placement and level of training were not correlated with an increased risk of complications, nor was time of day of CVC placement. In contrast, Merrer et al.showed that CVC insertion during nighttime was significantly associated with increased mechanical complications (odds ratio 2.06, 95% confidence interval, 1.04-4.08;,P = 0.03).5 This difference may be attributable to the fact that most of our ICUs now have a night float system rather than a more traditional 24-hour call model; therefore, trainees are less likely to be sleep deprived during CVC placement at night.

Severity of illness did not appear to significantly affect mechanical complication rates based on similar APACHE scores between the 2 groups. In addition, other indicators of illness severity (vasopressor use or lactate level) did not suggest that sicker patients may be more likely to experience mechanical complications than others. One could conjecture that perhaps sicker patients were more likely to have lines placed by more experienced trainees, although the present study design does not allow us to answer this question. Interestingly, ventilator use was associated with higher rates of complications. We cannot say definitively why this was the case; however, 1 contributing factor may be the physical constraints of placing the CVC around ventilator tubing.

Several unexpected findings surrounding attending supervision were noted: first, attending supervision appears to be significantly associated with increased complication rate, and second, trainees have negative perceptions regarding attending supervision. Eisen et al.showed a similar association between attending supervision and complication rate.3 It is possible that the increased complication rate is because sicker patients are more likely to have procedural supervision by attendings, attending physicians may be called to supervise when a CVC placement is not going as planned, or attendings may supervise more inexperienced operators. Reasons behind negative trainee attitudes surrounding supervision are unclear and literature on this topic is limited. This is an area that warrants further exploration in future studies.

Another unexpected finding is trainee practices regarding unsuccessful CVC placement; most trainees do not document failed procedures or order follow-up CXRs after unsuccessful CVC attempts. Given the higher risk of complications after unsuccessful CVCs, it is paramount that all physicians are trained to order postprocedure CXR to rule out pneumothorax or hemothorax. Furthermore, documentation of failed procedures is important for medical accuracy, transparency, and also hospital billing. It is unknown if these practices surrounding unsuccessful CVCs are institution-specific or more widespread. As far as we know, this is the first time that trainee practices regarding failed CVC placement have been published. Interestingly, while many current guidelines call attention to prevention, recognition, and management of central line-associated mechanical complications, specific recommendations about postprocedure behavior after failed CVC placement are not published.9-11 We feel it is critical that institutions reflect on their own practices, especially given that unsuccessful CVCs are shown to be correlated with a significant increase in complication rate. At our own institution, we have initiated an educational component of central line training for medicine trainees specifically addressing failed central line attempts.

This study has several limitations, including a retrospective study design at a single institution. There was a low overall number of complications, which reduced our ability to detect risk factors for complications and did not allow us to perform multivariable adjustment. Other limitations are that only documented CVC attempts were recorded and only those that met our search criteria. Lastly, not all notes contain information such as the number of attempts or peer supervision. Furthermore, the definition of CVC “attempt” is left to the operator’s discretion.

In conclusion, we observed a modern CVC mechanical complication rate of 1.9%. While the complication rate is similar to previous studies, there appear to be lower rates of pneumothorax and higher rates of bleeding complications. We also identified a deficit in trainee education regarding unsuccessful CVC placement; this is a novel finding and requires further investigation at other centers.

 

 

Disclosure: The authors have no conflicts of interest to report.

Files
References

1. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003;348(12):1123-1133. PubMed
2. Parienti JJ, Mongardon N, Mégarbane B, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med. 2015;373(13):1220-1229. PubMed
3. Eisen LA, Narasimhan M, Berger JS, Mayo PH, Rosen MJ, Schneider RF. Mechanical complications of central venous catheters. J Intensive Care Med. 2006;21(1):40-46. PubMed
4. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complications and failures of subclavian-vein catheterization. N Engl J Med. 1994;331(26):1735-1738. PubMed
5. Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: A randomized controlled trial. JAMA. 2001;286(6):700-707. PubMed
6. Steele R, Irvin CB. Central line mechanical complication rate in emergency medicine patients. Acad Emerg Med. 2001;8(2):204-207. PubMed
7. Calvache JA, Rodriguez MV, Trochez A, Klimek M, Stolker RJ, Lesaffre E. Incidence of mechanical complications of central venous catheterization using landmark technique: Do not try more than 3 times. J Intensive Care Med. 2016;31(6):397-402. PubMed
8. Barsuk JH, McDaghie WC, Cohen ER, Balachandran JS, Wayne DB. Use of simulation-based mastery learning to improve the quality of central venous catheter placement in a medical intensive care unit. J Hosp Med. 2009;4(7):397-403. PubMed
9. American Society of Anesthesiologists Task Force on Central Venous Access, Rupp SM, Apfelbaum JL, et al. Practice guidelines for central venous access: A report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2012;116(3):539-573. PubMed
10. Bodenham Chair A, Babu S, Bennett J, et al. Association of Anaesthetists of Great Britian and Irealand: Safe vascular access 2016. Anaesthesia. 2016;71:573-585. PubMed
11. Frykholm P, Pikwer A, Hammarskjöld F, et al. Clinical guidelines on central venous catheterisation. Swedish Society of Anaesthesiology and Intensic Care Medicine. Acta Anaesteshiol Scand. 2014;58(5):508-524. PubMed
12. Sekiguchi H, Tokita JE, Minami T, Eisen LA, Mayo PH, Narasimhan M. A prerotational, simulation-based workshop improves the safety of central venous catheter insertion: Results of a successful internal medicine house staff training program. Chest. 2011;140(3): 652-658. PubMed
13. Dong Y, Suri HS, Cook DA, et al. Simulation-based objective assessment discerns clinical proficiency in central line placement: A construct validation. Chest. 2010;137(5):1050-1056. PubMed
14. Evans LV, Dodge KL, Shah TD, et al. Simulation training in central venous catheter insertion: Improved performance in clinical practice. Acad Med. 2010;85(9):1462-1469. PubMed
15. Lefrant JY, Muller L, De La Coussaye JE et al. Risk factors of failure and immediate complication of subclavian vein catheterization in critically ill patients. Intensive Care Med. 2002;28(8):1036-1041. PubMed
16. Dariushnia SR, Wallace MJ, Siddigi NH, et al. Quality improvement guidelines for central venous access. J Vasc Interv Radiol. 2010;21(7):976-981. PubMed
17. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300-1305.e2. PubMed

Article PDF
Issue
Journal of Hospital Medicine 12 (8)
Publications
Topics
Page Number
646-651
Sections
Files
Files
Article PDF
Article PDF

Central venous catheter (CVC) placement is commonly performed in emergency and critical care settings for parenteral access, central monitoring, and hemodialysis. Although potentially lifesaving CVC insertion is associated with immediate risks including injury to nerves, vessels, and lungs.1-3 These “insertion-related complications” are of particular interest for several reasons. First, the frequency of such complications varies widely, with published rates between 1.4% and 33.2%.2-7 Reasons for such variation include differences in study definitions of complications (eg, pneumothorax and tip position),2,5 setting of CVC placement (eg, intensive care unit [ICU] vs emergency room), timing of placement (eg, elective vs emergent), differences in technique, and type of operator (eg, experienced vs learner). Thus, the precise incidence of such events in modern-day training settings with use of ultrasound guidance remains uncertain. Second, mechanical complications might be preventable with adequate training and supervision. Indeed, studies using simulation-based mastery techniques have demonstrated a reduction in rates of complications following intensive training.8 Finally, understanding risk factors associated with insertion complications might inform preventative strategies and improve patient safety.9-11

Few studies to date have examined trainees’ perceptions on CVC training, experience, supervision, and ability to recognize and prevent mechanical complications. While research investigating effects of simulation training has accumulated, most focus on successful completion of the procedure or individual procedural steps with little emphasis on operator perceptions.12-14 In addition, while multiple studies have shown that unsuccessful line attempts are a risk factor for CVC complications,3,4,7,15 there is very little known about trainee behavior and perceptions regarding unsuccessful line placement. CVC simulation trainings often assume successful completion of the procedure and do not address the crucial postprocedure steps that should be undertaken if a procedure is unsuccessful. For these reasons, we developed a survey to specifically examine trainee experience with CVC placement, supervision, postprocedural behavior, and attitudes regarding unsuccessful line placement.

Therefore, we designed a study with 2 specific goals: The first is to perform a contemporary analysis of CVC mechanical complication rate at an academic teaching institution and identify potential risk factors associated with these complications. Second, we sought to determine trainee perceptions regarding CVC complication experience, prevention, procedural supervision, and perceptions surrounding unsuccessful line placement.

METHODS

Design and Setting

We conducted a single-center retrospective review of nontunneled acute CVC procedures between June 1, 2014, and May 1, 2015, at the University of Michigan Health System (UMHS). UMHS is a tertiary care referral center with over 900 inpatient beds, including 99 ICU beds.

All residents in internal medicine, surgery, anesthesia, and emergency medicine receive mandatory education in CVC placement that includes an online training module and simulation-based training with competency assessment. Use of real-time ultrasound guidance is considered the standard of care for CVC placement.

Data Collection

Inpatient procedure notes were electronically searched for terms indicating CVC placement. This was performed by using our hospital’s Data Office for Clinical and Translational Research using the Electronic Medical Record Search Engine tool. Please see the supplemental materials for the full list of search terms. We electronically extracted data, including date of procedure, gender, and most recent body mass index (BMI), within 1 year prior to note. Acute Physiology and Chronic Health Evaluation III (APACHE III) data are tracked for all patients on admission to ICU; this was collected when available. Charts were then manually reviewed to collect additional data, including international normalized ratio (INR), platelet count, lactate level on the day of CVC placement, anticoagulant use (actively prescribed coumadin, therapeutic enoxaparin, therapeutic unfractionated heparin, or direct oral anticoagulant), ventilator or noninvasive positive pressure ventilation (NIPPV) at time of CVC placement, and vasopressor requirement within 24 hours of CVC placement. The procedure note was reviewed to gather information about site of CVC placement, size and type of catheter, number of attempts, procedural success, training level of the operator, and attending presence. Small bore CVCs were defined as 7 French (Fr) or lower. Large bore CVCs were defined as >7 Fr; this includes dialysis catheters, Cordis catheters (Cordis, Fremont, CA), and cooling catheters. The times of the procedure note and postprocedure chest x-ray (CXR) were recorded, including whether the CVC was placed on a weekend (Friday 7 pm to Sunday at midnight) or weekday.

 

 

Primary Outcome

The primary outcome was the rate of severe mechanical complications related to CVC placement. Similar to prior studies,2 we defined severe mechanical complications as arterial placement of dilator or catheter, hemothorax, pneumothorax, cerebral ischemia, patient death (related to procedure), significant hematoma, or vascular injury (defined as complication requiring expert consultation or blood product transfusion). We did not require a lower limit on blood transfusion. We considered pneumothorax a complication regardless of whether chest tube intervention was performed, as pneumothorax subjects the patient to additional tests (eg, serial CXRs) and sometimes symptoms (shortness of breath, pain, anxiety) regardless of whether or not a chest tube was required. Complications were confirmed by a direct review of procedure notes, progress notes, discharge summaries, and imaging studies.

Trainee Survey

A survey was electronically disseminated to all internal medicine and medicine-pediatric residents to inquire about CVC experiences, including time spent in the medical ICU, number of CVCs performed, postprocedure behavior for both failed and successful CVCs, and supervision experience and attitudes. Please see supplemental materials for full survey contents.

Statistical Methods

Descriptive statistics (percentage) were used to summarize data. Continuous and categorical variables were compared using Student t tests and chi-square tests, respectively. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).

Ethical and Regulatory Oversight

The study was deemed exempt by the University of Michigan Institutional Review Board (HUM00100549) as data collection was part of a quality improvement effort.

RESULTS

Demographics and Characteristics of Device Insertion

Between June 1, 2014, and May 1, 2015, 730 CVC procedure notes were reviewed (Table 1). The mean age of the study population was 58.9 years, and 41.6% (n = 304) were female. BMI data were available in 400 patients without complications and 5 patients with complications; the average BMI was 31.5 kg/m2. The APACHE III score was available for 442 patients without complications and 10 patients with complications; the average score was 86 (range 19-200). Most of the CVCs placed (n= 504, 69%) were small bore (<7 Fr). The majority of catheters were placed in the internal jugular (IJ) position (n = 525, 71.9%), followed by femoral (n = 144, 19.7%), subclavian (N = 57, 7.8%), and undocumented (n = 4, 0.6%). Ninety-six percent (n = 699) of CVCs were successfully placed. Seventy-six percent (n = 558) of procedure notes included documentation of the number of CVC attempts; of these, 85% documented 2 or fewer attempts. The majority of CVCs were placed by residents (n = 537, 73.9%), followed by fellows (N = 127, 17.5%) and attendings (n = 27, 3.7%). Attending supervision for all or key portions of CVC placement occurred 34.7% (n = 244) of the time overall and was lower for internal medicine trainees (n = 98/463, 21.2%) compared with surgical trainees (n = 73/127, 57.4%) or emergency medicine trainees (n = 62/96, 64.6%; P < 0.001). All successful IJ and subclavian CVCs except for 2 insertions (0.3%) had a postprocedure CXR. A minority of notes documented pressure transduction (4.5%) or blood gas analysis (0.2%) to confirm venous placement.

Lab data, information on utilization of anticoagulation, vasopressors, ventilation, and information on the use of transduction and blood gas data were collected for the first 410 uncomplicated patients and all patients that experienced complications (Table 2). The mean INR was 1.5 (range 0.9-9.7), mean platelets 180 K/uL (range 9-816 K/uL), and mean lactate 2.9 mmol/L (range 0.4-16 mmol/L). Twenty-one percent (n = 86) of patients were systemically anticoagulated at the time of CVC placement, 59% (n = 251) received vasopressors within 24 hours of CVC placement, and 63% (n = 265) were mechanically ventilated (Table 2).

Mechanical Complications

The mechanical complications identified included pneumothorax (n = 5), bleeding requiring transfusion (n = 3), vascular injury requiring expert consultation or intervention (n = 3), stroke (n = 1), and death (n = 2). Vascular injuries included 1 neck hematoma with superinfection requiring antibiotics, 1 neck hematoma requiring otolaryngology and vascular surgery consultation, and 1 venous dissection of IJ vein requiring vascular surgery consultation. None of these cases required operative intervention. The stroke was caused by inadvertent CVC placement into the carotid artery. One patient experienced tension pneumothorax and died due to this complication; this death occurred after 3 failed left subclavian CVC attempts and an ultimately successful CVC placement into left IJ vein. Another death occurred immediately following unsuccessful Cordis placement. As no autopsy was performed, it is impossible to know if the cause of death was the line placement. However, it would be prudent to consider this as a CVC complication given the temporal relationship to line placement. Thus, the total number of patients who experienced severe mechanical complications was 14 out of 730 (1.92%).

 

 

Risk Factors for Mechanical Complications

Certain patient factors were more commonly associated with complications. For example, BMI was significantly lower in the group that experienced complications vs those that did not (25.7 vs 31.0 kg/m2, P = 0.001). No other associations between demographic factors, including age (61.4 years vs 58.9 years, P = 0.57) or sex (57.1% male vs 41.3% female, P = 0.24), or admission APACHE III score (96 vs 86, P = 0.397) were noted. The mean INR, platelets, and lactate did not differ between the 2 groups. There was no difference between the use of vasopressors. Ventilator use (including endotracheal tube or NIPPV) was found to be significantly higher in the group that experienced mechanical complications (78.5% vs 65.9%, P = 0.001). Anticoagulation use was also associated with mechanical complications (28.6% vs 20.6%, P = 0.05); 3 patients on anticoagulation experienced significant hematomas. Mechanical complications were more common with subclavian location (21.4% vs 7.8%, P = 0.001); in all 3 cases involving subclavian CVC placement, the complication experienced was pneumothorax. The number of attempts significantly differed between the 2 groups, with an average of 1.5 attempts in the group without complications and 2.2 attempts in the group that experienced complications (P = 0.02). Additionally, rates of successful placement were lower among patients who experienced complications (78.6% vs 95.7%, P = 0.001).

With respect to operator characteristics, no significant difference between the levels of training was noted among those who experienced complications vs those who did not. Attending supervision was more frequent for the group that experienced complications (61.5% vs 34.2%, P = 0.04). There was no significant difference in complication rate according to the first vs the second half of the academic year (0.4% vs 0.3% per month, P = 0.30) or CVC placement during the day vs night (1.9% vs 2.0%, P = 0.97). A trend toward more complications in CVCs placed over the weekend compared to a weekday was observed (2.80% vs 1.23%, P = 0.125).

Unsuccessful CVCs

There were 30 documented unsuccessful CVC procedures, representing 4.1% of all procedures. Of these, 3 procedures had complications; these included 2 pneumothoraxes (1 leading to death) and 1 unexplained death. Twenty-four of the unsuccessful CVC attempts were in either the subclavian or IJ location; of these, 5 (21%) did not have a postprocedure CXR obtained.

Survey Results

The survey was completed by 103 out of 166 internal medicine residents (62% response rate). Of these, 55% (n = 57) reported having performed 5 or more CVCs, and 14% (n = 14) had performed more than 15 CVCs.

All respondents who had performed at least 1 CVC (n = 80) were asked about their perceptions regarding attending supervision. Eighty-one percent (n = 65/80) responded that they have never been directly supervised by an attending during CVC placement, while 16% (n = 13/80) reported being supervised less than 25% of the time. Most (n = 53/75, 71%) did not feel that attending supervision affected their performance, while 21% (n = 16/75) felt it affected performance negatively, and only 8% (n = 6/75) stated it affected performance positively. Nineteen percent (n = 15/80) indicated that they prefer more supervision by attendings, while 35% (n = 28/80) did not wish for more attending supervision, and 46% (n = 37/80) were indifferent.

All respondents who had performed at least 1 CVC were asked about postprocedure protocols. The vast majority (n = 77/80, 95%) reported documenting a postprocedure note more than 75% of the time after a successful procedure; in contrast, only 38% (n = 30/80) of those who had failed a CVC placement reported documenting a procedure note more than 75% of the time (Figure 1). Only 35% (n = 21/60) of respondents reported routinely (100% of the time) ordering a CXR after a failed chest CVC attempt (Figure 2), and 47% (n = 28/60) only ordered a CXR if they were concerned there was a complication. Most (69%, n = 55/80) felt it was important to order a CXR after a failed chest CVC placement, while 6% (n = 5/80) did not feel it was important, and 25% (n = 20/80) did not know or were indifferent.

DISCUSSION

We performed a contemporary analysis of CVC placement at an academic tertiary care center and observed a rate of severe mechanical complications of 1.9%. This rate is within previously described acceptable thresholds.16 Our study adds to the literature by identifying several important risk factors for development of mechanical complications. We confirm many risk factors that have been noted historically, such as subclavian line location,2,3 attending supervision,3 low BMI,4 number of CVC attempts, and unsuccessful CVC placement.3,4,7,15 We identified several unique risk factors, including systemic anticoagulation as well as ventilator use. Lastly, we identified unexpected deficits in trainee knowledge surrounding management of failed CVCs and negative attitudes regarding attending supervision.

 

 

Most existing literature evaluated risk factors for CVC complication prior to routine ultrasound use;3-5,7,15 surprisingly, it appears that severe mechanical complications do not differ dramatically in the real-time ultrasound era. Eisen et al.3 prospectively studied CVC placement at an academic medical center and found a severe mechanical complication rate (as defined in our paper) of 1.9% due to pneumothorax (1.3%), hemothorax (0.3%), and death (0.3%).We would expect the number of complications to decrease in the postultrasound era, and indeed it appears that pneumothoraces have decreased likely due to ultrasound guidance and decrease in subclavian location. However, in contrast, rates of significant hematomas and bleeding are higher in our study. Although we are unable to state why this may be the case, increasing use of anticoagulation in the general population might explain this finding.17 For instance, of the 6 patients who experienced hematomas or vascular injuries in our study, 3 were on anticoagulation at the time of CVC placement.

Interestingly, time of academic year of CVC placement and level of training were not correlated with an increased risk of complications, nor was time of day of CVC placement. In contrast, Merrer et al.showed that CVC insertion during nighttime was significantly associated with increased mechanical complications (odds ratio 2.06, 95% confidence interval, 1.04-4.08;,P = 0.03).5 This difference may be attributable to the fact that most of our ICUs now have a night float system rather than a more traditional 24-hour call model; therefore, trainees are less likely to be sleep deprived during CVC placement at night.

Severity of illness did not appear to significantly affect mechanical complication rates based on similar APACHE scores between the 2 groups. In addition, other indicators of illness severity (vasopressor use or lactate level) did not suggest that sicker patients may be more likely to experience mechanical complications than others. One could conjecture that perhaps sicker patients were more likely to have lines placed by more experienced trainees, although the present study design does not allow us to answer this question. Interestingly, ventilator use was associated with higher rates of complications. We cannot say definitively why this was the case; however, 1 contributing factor may be the physical constraints of placing the CVC around ventilator tubing.

Several unexpected findings surrounding attending supervision were noted: first, attending supervision appears to be significantly associated with increased complication rate, and second, trainees have negative perceptions regarding attending supervision. Eisen et al.showed a similar association between attending supervision and complication rate.3 It is possible that the increased complication rate is because sicker patients are more likely to have procedural supervision by attendings, attending physicians may be called to supervise when a CVC placement is not going as planned, or attendings may supervise more inexperienced operators. Reasons behind negative trainee attitudes surrounding supervision are unclear and literature on this topic is limited. This is an area that warrants further exploration in future studies.

Another unexpected finding is trainee practices regarding unsuccessful CVC placement; most trainees do not document failed procedures or order follow-up CXRs after unsuccessful CVC attempts. Given the higher risk of complications after unsuccessful CVCs, it is paramount that all physicians are trained to order postprocedure CXR to rule out pneumothorax or hemothorax. Furthermore, documentation of failed procedures is important for medical accuracy, transparency, and also hospital billing. It is unknown if these practices surrounding unsuccessful CVCs are institution-specific or more widespread. As far as we know, this is the first time that trainee practices regarding failed CVC placement have been published. Interestingly, while many current guidelines call attention to prevention, recognition, and management of central line-associated mechanical complications, specific recommendations about postprocedure behavior after failed CVC placement are not published.9-11 We feel it is critical that institutions reflect on their own practices, especially given that unsuccessful CVCs are shown to be correlated with a significant increase in complication rate. At our own institution, we have initiated an educational component of central line training for medicine trainees specifically addressing failed central line attempts.

This study has several limitations, including a retrospective study design at a single institution. There was a low overall number of complications, which reduced our ability to detect risk factors for complications and did not allow us to perform multivariable adjustment. Other limitations are that only documented CVC attempts were recorded and only those that met our search criteria. Lastly, not all notes contain information such as the number of attempts or peer supervision. Furthermore, the definition of CVC “attempt” is left to the operator’s discretion.

In conclusion, we observed a modern CVC mechanical complication rate of 1.9%. While the complication rate is similar to previous studies, there appear to be lower rates of pneumothorax and higher rates of bleeding complications. We also identified a deficit in trainee education regarding unsuccessful CVC placement; this is a novel finding and requires further investigation at other centers.

 

 

Disclosure: The authors have no conflicts of interest to report.

Central venous catheter (CVC) placement is commonly performed in emergency and critical care settings for parenteral access, central monitoring, and hemodialysis. Although potentially lifesaving CVC insertion is associated with immediate risks including injury to nerves, vessels, and lungs.1-3 These “insertion-related complications” are of particular interest for several reasons. First, the frequency of such complications varies widely, with published rates between 1.4% and 33.2%.2-7 Reasons for such variation include differences in study definitions of complications (eg, pneumothorax and tip position),2,5 setting of CVC placement (eg, intensive care unit [ICU] vs emergency room), timing of placement (eg, elective vs emergent), differences in technique, and type of operator (eg, experienced vs learner). Thus, the precise incidence of such events in modern-day training settings with use of ultrasound guidance remains uncertain. Second, mechanical complications might be preventable with adequate training and supervision. Indeed, studies using simulation-based mastery techniques have demonstrated a reduction in rates of complications following intensive training.8 Finally, understanding risk factors associated with insertion complications might inform preventative strategies and improve patient safety.9-11

Few studies to date have examined trainees’ perceptions on CVC training, experience, supervision, and ability to recognize and prevent mechanical complications. While research investigating effects of simulation training has accumulated, most focus on successful completion of the procedure or individual procedural steps with little emphasis on operator perceptions.12-14 In addition, while multiple studies have shown that unsuccessful line attempts are a risk factor for CVC complications,3,4,7,15 there is very little known about trainee behavior and perceptions regarding unsuccessful line placement. CVC simulation trainings often assume successful completion of the procedure and do not address the crucial postprocedure steps that should be undertaken if a procedure is unsuccessful. For these reasons, we developed a survey to specifically examine trainee experience with CVC placement, supervision, postprocedural behavior, and attitudes regarding unsuccessful line placement.

Therefore, we designed a study with 2 specific goals: The first is to perform a contemporary analysis of CVC mechanical complication rate at an academic teaching institution and identify potential risk factors associated with these complications. Second, we sought to determine trainee perceptions regarding CVC complication experience, prevention, procedural supervision, and perceptions surrounding unsuccessful line placement.

METHODS

Design and Setting

We conducted a single-center retrospective review of nontunneled acute CVC procedures between June 1, 2014, and May 1, 2015, at the University of Michigan Health System (UMHS). UMHS is a tertiary care referral center with over 900 inpatient beds, including 99 ICU beds.

All residents in internal medicine, surgery, anesthesia, and emergency medicine receive mandatory education in CVC placement that includes an online training module and simulation-based training with competency assessment. Use of real-time ultrasound guidance is considered the standard of care for CVC placement.

Data Collection

Inpatient procedure notes were electronically searched for terms indicating CVC placement. This was performed by using our hospital’s Data Office for Clinical and Translational Research using the Electronic Medical Record Search Engine tool. Please see the supplemental materials for the full list of search terms. We electronically extracted data, including date of procedure, gender, and most recent body mass index (BMI), within 1 year prior to note. Acute Physiology and Chronic Health Evaluation III (APACHE III) data are tracked for all patients on admission to ICU; this was collected when available. Charts were then manually reviewed to collect additional data, including international normalized ratio (INR), platelet count, lactate level on the day of CVC placement, anticoagulant use (actively prescribed coumadin, therapeutic enoxaparin, therapeutic unfractionated heparin, or direct oral anticoagulant), ventilator or noninvasive positive pressure ventilation (NIPPV) at time of CVC placement, and vasopressor requirement within 24 hours of CVC placement. The procedure note was reviewed to gather information about site of CVC placement, size and type of catheter, number of attempts, procedural success, training level of the operator, and attending presence. Small bore CVCs were defined as 7 French (Fr) or lower. Large bore CVCs were defined as >7 Fr; this includes dialysis catheters, Cordis catheters (Cordis, Fremont, CA), and cooling catheters. The times of the procedure note and postprocedure chest x-ray (CXR) were recorded, including whether the CVC was placed on a weekend (Friday 7 pm to Sunday at midnight) or weekday.

 

 

Primary Outcome

The primary outcome was the rate of severe mechanical complications related to CVC placement. Similar to prior studies,2 we defined severe mechanical complications as arterial placement of dilator or catheter, hemothorax, pneumothorax, cerebral ischemia, patient death (related to procedure), significant hematoma, or vascular injury (defined as complication requiring expert consultation or blood product transfusion). We did not require a lower limit on blood transfusion. We considered pneumothorax a complication regardless of whether chest tube intervention was performed, as pneumothorax subjects the patient to additional tests (eg, serial CXRs) and sometimes symptoms (shortness of breath, pain, anxiety) regardless of whether or not a chest tube was required. Complications were confirmed by a direct review of procedure notes, progress notes, discharge summaries, and imaging studies.

Trainee Survey

A survey was electronically disseminated to all internal medicine and medicine-pediatric residents to inquire about CVC experiences, including time spent in the medical ICU, number of CVCs performed, postprocedure behavior for both failed and successful CVCs, and supervision experience and attitudes. Please see supplemental materials for full survey contents.

Statistical Methods

Descriptive statistics (percentage) were used to summarize data. Continuous and categorical variables were compared using Student t tests and chi-square tests, respectively. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).

Ethical and Regulatory Oversight

The study was deemed exempt by the University of Michigan Institutional Review Board (HUM00100549) as data collection was part of a quality improvement effort.

RESULTS

Demographics and Characteristics of Device Insertion

Between June 1, 2014, and May 1, 2015, 730 CVC procedure notes were reviewed (Table 1). The mean age of the study population was 58.9 years, and 41.6% (n = 304) were female. BMI data were available in 400 patients without complications and 5 patients with complications; the average BMI was 31.5 kg/m2. The APACHE III score was available for 442 patients without complications and 10 patients with complications; the average score was 86 (range 19-200). Most of the CVCs placed (n= 504, 69%) were small bore (<7 Fr). The majority of catheters were placed in the internal jugular (IJ) position (n = 525, 71.9%), followed by femoral (n = 144, 19.7%), subclavian (N = 57, 7.8%), and undocumented (n = 4, 0.6%). Ninety-six percent (n = 699) of CVCs were successfully placed. Seventy-six percent (n = 558) of procedure notes included documentation of the number of CVC attempts; of these, 85% documented 2 or fewer attempts. The majority of CVCs were placed by residents (n = 537, 73.9%), followed by fellows (N = 127, 17.5%) and attendings (n = 27, 3.7%). Attending supervision for all or key portions of CVC placement occurred 34.7% (n = 244) of the time overall and was lower for internal medicine trainees (n = 98/463, 21.2%) compared with surgical trainees (n = 73/127, 57.4%) or emergency medicine trainees (n = 62/96, 64.6%; P < 0.001). All successful IJ and subclavian CVCs except for 2 insertions (0.3%) had a postprocedure CXR. A minority of notes documented pressure transduction (4.5%) or blood gas analysis (0.2%) to confirm venous placement.

Lab data, information on utilization of anticoagulation, vasopressors, ventilation, and information on the use of transduction and blood gas data were collected for the first 410 uncomplicated patients and all patients that experienced complications (Table 2). The mean INR was 1.5 (range 0.9-9.7), mean platelets 180 K/uL (range 9-816 K/uL), and mean lactate 2.9 mmol/L (range 0.4-16 mmol/L). Twenty-one percent (n = 86) of patients were systemically anticoagulated at the time of CVC placement, 59% (n = 251) received vasopressors within 24 hours of CVC placement, and 63% (n = 265) were mechanically ventilated (Table 2).

Mechanical Complications

The mechanical complications identified included pneumothorax (n = 5), bleeding requiring transfusion (n = 3), vascular injury requiring expert consultation or intervention (n = 3), stroke (n = 1), and death (n = 2). Vascular injuries included 1 neck hematoma with superinfection requiring antibiotics, 1 neck hematoma requiring otolaryngology and vascular surgery consultation, and 1 venous dissection of IJ vein requiring vascular surgery consultation. None of these cases required operative intervention. The stroke was caused by inadvertent CVC placement into the carotid artery. One patient experienced tension pneumothorax and died due to this complication; this death occurred after 3 failed left subclavian CVC attempts and an ultimately successful CVC placement into left IJ vein. Another death occurred immediately following unsuccessful Cordis placement. As no autopsy was performed, it is impossible to know if the cause of death was the line placement. However, it would be prudent to consider this as a CVC complication given the temporal relationship to line placement. Thus, the total number of patients who experienced severe mechanical complications was 14 out of 730 (1.92%).

 

 

Risk Factors for Mechanical Complications

Certain patient factors were more commonly associated with complications. For example, BMI was significantly lower in the group that experienced complications vs those that did not (25.7 vs 31.0 kg/m2, P = 0.001). No other associations between demographic factors, including age (61.4 years vs 58.9 years, P = 0.57) or sex (57.1% male vs 41.3% female, P = 0.24), or admission APACHE III score (96 vs 86, P = 0.397) were noted. The mean INR, platelets, and lactate did not differ between the 2 groups. There was no difference between the use of vasopressors. Ventilator use (including endotracheal tube or NIPPV) was found to be significantly higher in the group that experienced mechanical complications (78.5% vs 65.9%, P = 0.001). Anticoagulation use was also associated with mechanical complications (28.6% vs 20.6%, P = 0.05); 3 patients on anticoagulation experienced significant hematomas. Mechanical complications were more common with subclavian location (21.4% vs 7.8%, P = 0.001); in all 3 cases involving subclavian CVC placement, the complication experienced was pneumothorax. The number of attempts significantly differed between the 2 groups, with an average of 1.5 attempts in the group without complications and 2.2 attempts in the group that experienced complications (P = 0.02). Additionally, rates of successful placement were lower among patients who experienced complications (78.6% vs 95.7%, P = 0.001).

With respect to operator characteristics, no significant difference between the levels of training was noted among those who experienced complications vs those who did not. Attending supervision was more frequent for the group that experienced complications (61.5% vs 34.2%, P = 0.04). There was no significant difference in complication rate according to the first vs the second half of the academic year (0.4% vs 0.3% per month, P = 0.30) or CVC placement during the day vs night (1.9% vs 2.0%, P = 0.97). A trend toward more complications in CVCs placed over the weekend compared to a weekday was observed (2.80% vs 1.23%, P = 0.125).

Unsuccessful CVCs

There were 30 documented unsuccessful CVC procedures, representing 4.1% of all procedures. Of these, 3 procedures had complications; these included 2 pneumothoraxes (1 leading to death) and 1 unexplained death. Twenty-four of the unsuccessful CVC attempts were in either the subclavian or IJ location; of these, 5 (21%) did not have a postprocedure CXR obtained.

Survey Results

The survey was completed by 103 out of 166 internal medicine residents (62% response rate). Of these, 55% (n = 57) reported having performed 5 or more CVCs, and 14% (n = 14) had performed more than 15 CVCs.

All respondents who had performed at least 1 CVC (n = 80) were asked about their perceptions regarding attending supervision. Eighty-one percent (n = 65/80) responded that they have never been directly supervised by an attending during CVC placement, while 16% (n = 13/80) reported being supervised less than 25% of the time. Most (n = 53/75, 71%) did not feel that attending supervision affected their performance, while 21% (n = 16/75) felt it affected performance negatively, and only 8% (n = 6/75) stated it affected performance positively. Nineteen percent (n = 15/80) indicated that they prefer more supervision by attendings, while 35% (n = 28/80) did not wish for more attending supervision, and 46% (n = 37/80) were indifferent.

All respondents who had performed at least 1 CVC were asked about postprocedure protocols. The vast majority (n = 77/80, 95%) reported documenting a postprocedure note more than 75% of the time after a successful procedure; in contrast, only 38% (n = 30/80) of those who had failed a CVC placement reported documenting a procedure note more than 75% of the time (Figure 1). Only 35% (n = 21/60) of respondents reported routinely (100% of the time) ordering a CXR after a failed chest CVC attempt (Figure 2), and 47% (n = 28/60) only ordered a CXR if they were concerned there was a complication. Most (69%, n = 55/80) felt it was important to order a CXR after a failed chest CVC placement, while 6% (n = 5/80) did not feel it was important, and 25% (n = 20/80) did not know or were indifferent.

DISCUSSION

We performed a contemporary analysis of CVC placement at an academic tertiary care center and observed a rate of severe mechanical complications of 1.9%. This rate is within previously described acceptable thresholds.16 Our study adds to the literature by identifying several important risk factors for development of mechanical complications. We confirm many risk factors that have been noted historically, such as subclavian line location,2,3 attending supervision,3 low BMI,4 number of CVC attempts, and unsuccessful CVC placement.3,4,7,15 We identified several unique risk factors, including systemic anticoagulation as well as ventilator use. Lastly, we identified unexpected deficits in trainee knowledge surrounding management of failed CVCs and negative attitudes regarding attending supervision.

 

 

Most existing literature evaluated risk factors for CVC complication prior to routine ultrasound use;3-5,7,15 surprisingly, it appears that severe mechanical complications do not differ dramatically in the real-time ultrasound era. Eisen et al.3 prospectively studied CVC placement at an academic medical center and found a severe mechanical complication rate (as defined in our paper) of 1.9% due to pneumothorax (1.3%), hemothorax (0.3%), and death (0.3%).We would expect the number of complications to decrease in the postultrasound era, and indeed it appears that pneumothoraces have decreased likely due to ultrasound guidance and decrease in subclavian location. However, in contrast, rates of significant hematomas and bleeding are higher in our study. Although we are unable to state why this may be the case, increasing use of anticoagulation in the general population might explain this finding.17 For instance, of the 6 patients who experienced hematomas or vascular injuries in our study, 3 were on anticoagulation at the time of CVC placement.

Interestingly, time of academic year of CVC placement and level of training were not correlated with an increased risk of complications, nor was time of day of CVC placement. In contrast, Merrer et al.showed that CVC insertion during nighttime was significantly associated with increased mechanical complications (odds ratio 2.06, 95% confidence interval, 1.04-4.08;,P = 0.03).5 This difference may be attributable to the fact that most of our ICUs now have a night float system rather than a more traditional 24-hour call model; therefore, trainees are less likely to be sleep deprived during CVC placement at night.

Severity of illness did not appear to significantly affect mechanical complication rates based on similar APACHE scores between the 2 groups. In addition, other indicators of illness severity (vasopressor use or lactate level) did not suggest that sicker patients may be more likely to experience mechanical complications than others. One could conjecture that perhaps sicker patients were more likely to have lines placed by more experienced trainees, although the present study design does not allow us to answer this question. Interestingly, ventilator use was associated with higher rates of complications. We cannot say definitively why this was the case; however, 1 contributing factor may be the physical constraints of placing the CVC around ventilator tubing.

Several unexpected findings surrounding attending supervision were noted: first, attending supervision appears to be significantly associated with increased complication rate, and second, trainees have negative perceptions regarding attending supervision. Eisen et al.showed a similar association between attending supervision and complication rate.3 It is possible that the increased complication rate is because sicker patients are more likely to have procedural supervision by attendings, attending physicians may be called to supervise when a CVC placement is not going as planned, or attendings may supervise more inexperienced operators. Reasons behind negative trainee attitudes surrounding supervision are unclear and literature on this topic is limited. This is an area that warrants further exploration in future studies.

Another unexpected finding is trainee practices regarding unsuccessful CVC placement; most trainees do not document failed procedures or order follow-up CXRs after unsuccessful CVC attempts. Given the higher risk of complications after unsuccessful CVCs, it is paramount that all physicians are trained to order postprocedure CXR to rule out pneumothorax or hemothorax. Furthermore, documentation of failed procedures is important for medical accuracy, transparency, and also hospital billing. It is unknown if these practices surrounding unsuccessful CVCs are institution-specific or more widespread. As far as we know, this is the first time that trainee practices regarding failed CVC placement have been published. Interestingly, while many current guidelines call attention to prevention, recognition, and management of central line-associated mechanical complications, specific recommendations about postprocedure behavior after failed CVC placement are not published.9-11 We feel it is critical that institutions reflect on their own practices, especially given that unsuccessful CVCs are shown to be correlated with a significant increase in complication rate. At our own institution, we have initiated an educational component of central line training for medicine trainees specifically addressing failed central line attempts.

This study has several limitations, including a retrospective study design at a single institution. There was a low overall number of complications, which reduced our ability to detect risk factors for complications and did not allow us to perform multivariable adjustment. Other limitations are that only documented CVC attempts were recorded and only those that met our search criteria. Lastly, not all notes contain information such as the number of attempts or peer supervision. Furthermore, the definition of CVC “attempt” is left to the operator’s discretion.

In conclusion, we observed a modern CVC mechanical complication rate of 1.9%. While the complication rate is similar to previous studies, there appear to be lower rates of pneumothorax and higher rates of bleeding complications. We also identified a deficit in trainee education regarding unsuccessful CVC placement; this is a novel finding and requires further investigation at other centers.

 

 

Disclosure: The authors have no conflicts of interest to report.

References

1. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003;348(12):1123-1133. PubMed
2. Parienti JJ, Mongardon N, Mégarbane B, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med. 2015;373(13):1220-1229. PubMed
3. Eisen LA, Narasimhan M, Berger JS, Mayo PH, Rosen MJ, Schneider RF. Mechanical complications of central venous catheters. J Intensive Care Med. 2006;21(1):40-46. PubMed
4. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complications and failures of subclavian-vein catheterization. N Engl J Med. 1994;331(26):1735-1738. PubMed
5. Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: A randomized controlled trial. JAMA. 2001;286(6):700-707. PubMed
6. Steele R, Irvin CB. Central line mechanical complication rate in emergency medicine patients. Acad Emerg Med. 2001;8(2):204-207. PubMed
7. Calvache JA, Rodriguez MV, Trochez A, Klimek M, Stolker RJ, Lesaffre E. Incidence of mechanical complications of central venous catheterization using landmark technique: Do not try more than 3 times. J Intensive Care Med. 2016;31(6):397-402. PubMed
8. Barsuk JH, McDaghie WC, Cohen ER, Balachandran JS, Wayne DB. Use of simulation-based mastery learning to improve the quality of central venous catheter placement in a medical intensive care unit. J Hosp Med. 2009;4(7):397-403. PubMed
9. American Society of Anesthesiologists Task Force on Central Venous Access, Rupp SM, Apfelbaum JL, et al. Practice guidelines for central venous access: A report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2012;116(3):539-573. PubMed
10. Bodenham Chair A, Babu S, Bennett J, et al. Association of Anaesthetists of Great Britian and Irealand: Safe vascular access 2016. Anaesthesia. 2016;71:573-585. PubMed
11. Frykholm P, Pikwer A, Hammarskjöld F, et al. Clinical guidelines on central venous catheterisation. Swedish Society of Anaesthesiology and Intensic Care Medicine. Acta Anaesteshiol Scand. 2014;58(5):508-524. PubMed
12. Sekiguchi H, Tokita JE, Minami T, Eisen LA, Mayo PH, Narasimhan M. A prerotational, simulation-based workshop improves the safety of central venous catheter insertion: Results of a successful internal medicine house staff training program. Chest. 2011;140(3): 652-658. PubMed
13. Dong Y, Suri HS, Cook DA, et al. Simulation-based objective assessment discerns clinical proficiency in central line placement: A construct validation. Chest. 2010;137(5):1050-1056. PubMed
14. Evans LV, Dodge KL, Shah TD, et al. Simulation training in central venous catheter insertion: Improved performance in clinical practice. Acad Med. 2010;85(9):1462-1469. PubMed
15. Lefrant JY, Muller L, De La Coussaye JE et al. Risk factors of failure and immediate complication of subclavian vein catheterization in critically ill patients. Intensive Care Med. 2002;28(8):1036-1041. PubMed
16. Dariushnia SR, Wallace MJ, Siddigi NH, et al. Quality improvement guidelines for central venous access. J Vasc Interv Radiol. 2010;21(7):976-981. PubMed
17. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300-1305.e2. PubMed

References

1. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003;348(12):1123-1133. PubMed
2. Parienti JJ, Mongardon N, Mégarbane B, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med. 2015;373(13):1220-1229. PubMed
3. Eisen LA, Narasimhan M, Berger JS, Mayo PH, Rosen MJ, Schneider RF. Mechanical complications of central venous catheters. J Intensive Care Med. 2006;21(1):40-46. PubMed
4. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complications and failures of subclavian-vein catheterization. N Engl J Med. 1994;331(26):1735-1738. PubMed
5. Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: A randomized controlled trial. JAMA. 2001;286(6):700-707. PubMed
6. Steele R, Irvin CB. Central line mechanical complication rate in emergency medicine patients. Acad Emerg Med. 2001;8(2):204-207. PubMed
7. Calvache JA, Rodriguez MV, Trochez A, Klimek M, Stolker RJ, Lesaffre E. Incidence of mechanical complications of central venous catheterization using landmark technique: Do not try more than 3 times. J Intensive Care Med. 2016;31(6):397-402. PubMed
8. Barsuk JH, McDaghie WC, Cohen ER, Balachandran JS, Wayne DB. Use of simulation-based mastery learning to improve the quality of central venous catheter placement in a medical intensive care unit. J Hosp Med. 2009;4(7):397-403. PubMed
9. American Society of Anesthesiologists Task Force on Central Venous Access, Rupp SM, Apfelbaum JL, et al. Practice guidelines for central venous access: A report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2012;116(3):539-573. PubMed
10. Bodenham Chair A, Babu S, Bennett J, et al. Association of Anaesthetists of Great Britian and Irealand: Safe vascular access 2016. Anaesthesia. 2016;71:573-585. PubMed
11. Frykholm P, Pikwer A, Hammarskjöld F, et al. Clinical guidelines on central venous catheterisation. Swedish Society of Anaesthesiology and Intensic Care Medicine. Acta Anaesteshiol Scand. 2014;58(5):508-524. PubMed
12. Sekiguchi H, Tokita JE, Minami T, Eisen LA, Mayo PH, Narasimhan M. A prerotational, simulation-based workshop improves the safety of central venous catheter insertion: Results of a successful internal medicine house staff training program. Chest. 2011;140(3): 652-658. PubMed
13. Dong Y, Suri HS, Cook DA, et al. Simulation-based objective assessment discerns clinical proficiency in central line placement: A construct validation. Chest. 2010;137(5):1050-1056. PubMed
14. Evans LV, Dodge KL, Shah TD, et al. Simulation training in central venous catheter insertion: Improved performance in clinical practice. Acad Med. 2010;85(9):1462-1469. PubMed
15. Lefrant JY, Muller L, De La Coussaye JE et al. Risk factors of failure and immediate complication of subclavian vein catheterization in critically ill patients. Intensive Care Med. 2002;28(8):1036-1041. PubMed
16. Dariushnia SR, Wallace MJ, Siddigi NH, et al. Quality improvement guidelines for central venous access. J Vasc Interv Radiol. 2010;21(7):976-981. PubMed
17. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300-1305.e2. PubMed

Issue
Journal of Hospital Medicine 12 (8)
Issue
Journal of Hospital Medicine 12 (8)
Page Number
646-651
Page Number
646-651
Publications
Publications
Topics
Article Type
Display Headline
A Contemporary Assessment of Mechanical Complication Rates and Trainee Perceptions of Central Venous Catheter Insertion
Display Headline
A Contemporary Assessment of Mechanical Complication Rates and Trainee Perceptions of Central Venous Catheter Insertion
Sections
Article Source

© 2017 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Michael Heung, MD, MS, 1500 E. Medical Center Drive, SC 5364, Ann Arbor, MI 48109-5364; Telephone: 734-936-6489; Fax: 734-936-9621; E-mail: mheung@umich.edu
Content Gating
Gated (full article locked unless allowed per User)
Alternative CME
Disqus Comments
Default
Gating Strategy
First Peek Free
Article PDF Media
Media Files

Inherited Thrombophilia Testing

Article Type
Changed
Sun, 03/03/2019 - 07:12
Display Headline
Inpatient inherited thrombophilia testing

The Things We Do for No Reason (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent black and white conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Inherited thrombophilia refers to a genetic condition that predisposes to an increased risk of venous thromboembolism (VTE). This disorder is prevalent in approximately 7% of the population and includes mutations such as factor V Leiden, prothrombin 20210, protein C deficiency, protein S deficiency, antithrombin deficiency, and methylene tetrahydrofolate reductase. The relative risk of VTE is 3‐ to 20‐fold greater in patients with inherited thrombophilia compared with the general population. Is testing for inherited thrombophilia recommended? The available evidence suggests that testing for inherited thrombophilia is not recommended in most clinical settings. In patients without a personal history of VTE, thrombophilia results do not change management, as there is no evidence to support thromboprophylaxis in this setting. In patients with a personal history of provoked or unprovoked VTE, inpatient testing is not indicated, as results do not influence management, testing is not cost‐effective, and a positive test result may lead to unnecessary patient anxiety or may result in unnecessary involvement of consultants. Testing in hospitalized patients has even more limitations because many thrombophilia tests are inaccurate in the setting of acute VTE and/or anticoagulation.

CASE PRESENTATION

A 23‐year‐old man presents to the emergency room with pleuritic chest pain and new oxygen requirement of 2 L nasal cannula. He has a history of unprovoked lower extremity deep venous thrombosis (DVT) diagnosed at age 20 and completed 3 months of systemic anticoagulation without complications. He reports no family history of clotting disorders or venous thromboembolism (VTE) and no reversible risk factors for VTE such as prolonged immobility, recent surgery, or high‐risk medications. A computed tomogram pulmonary embolism protocol shows multiple right lower lobe, segmental pulmonary emboli. Anticoagulation is initiated, and the patient is admitted to the hospital. Will inpatient inherited thrombophilia testing impact management for this case?

WHY MAY INHERITED THROMBOPHILIA TESTING PROVE HELPFUL?

The annual incidence rate of a first VTE event is estimated as 117 per 100,000 individuals per year.[1] The most common presentations are symptomatic DVT of the leg (annual incidence approximately 48 per 100,000 people), or a pulmonary embolism (annual incidence approximately 69 per 100,000 people).[1] Pulmonary embolism results in death in up to 30% of untreated patients and 2.5% of patients who receive systemic anticoagulation.[2] Principal in the pathogenesis of VTE are factors described by Virchow's triad: venous stasis, endothelial injury, and systemic hypercoagulability. By identifying a mutation in 1 or more of the factors in the clotting pathway, an evaluation for inherited thrombophilia theoretically may unearth factors that drive systemic hypercoagulability and inform decision making so as to prevent future events.

Inherited thrombophilia refers to a genetic condition that predisposes to an increased risk of VTE.[3] Approximately 7% of the general population has inherited thrombophilia, which includes factor V Leiden (FVL) mutation, prothrombin 20210 mutation (PT20210), protein C deficiency, protein S deficiency, antithrombin III (ATIII) deficiency, and methylene tetrahydrofolate reductase mutation (MTHFR).[4] Of note, the definition does not include acquired etiologies, such as antiphospholipid antibody syndrome. Depending on the underlying condition and expression of the genetic abnormality, the relative risk of VTE in patients with inherited thrombophilia is 3‐ to 20‐fold greater than that of the general population.[5] Therefore, it is logical to consider that testing for inherited thrombophilia might be clinically useful. However, the evidence for doing so is very limited.

DOES INHERITED THROMBOPHILIA TESTING CHANGE MANAGEMENT?

An inherited thrombophilia evaluation is unlikely to affect management in most clinical settings. There is no current evidence to support primary prophylaxis[6] nor is there evidence that management of patients with recurrent VTE should be altered in the setting of inherited thrombophilia.

To date, no prospective trials have evaluated the efficacy of anticoagulant use for primary prevention of VTE in patients with inherited thrombophilia.[6] Given the limited evidence for thromboprophylaxis and risks of anticoagulation, primary prevention for patients with inherited thrombophilia that remain asymptomatic is not recommended by the current American College of Chest Physicians guidelines.[7, 8]

Similarly, in patients with a first VTE or recurrent VTE, diagnosis of inherited thrombophilia is often not associated with recurrent events, which suggests that other nongenetic factors may be just as important, if not more important, in determining the risk of recurrence.[9] Although no randomized controlled or controlled clinical trials have evaluated the effects of testing for inherited thrombophilia on recurrent VTE,[10, 11] several prospective studies have assessed risk factors for recurrence. Data from these studies suggest that recurrence rates after unprovoked VTE are only weakly correlated with inherited thrombophilia status.[12, 13] Rather, it is postulated that patients with recurrent VTE may exhibit a prothrombotic tendency regardless of underlying genetic predisposition. In this case, decisions regarding anticoagulation do not vary by thrombophilia status. Instead, thrombophilia testing may divert attention away from the management of more prevalent, potentially modifiable risk factors such as immobility, oral contraceptive use, or malignancy, all of which are associated with recurrent VTE.[14] These provoking factors are the most important determinants of the chance of VTE recurrence as well as the most significant factors to take into account when deciding duration of anticoagulation.

Christiansen et al. performed a prospective study evaluating the association between recurrent VTE and thrombophilia status. After following 474 patients with confirmed first episode VTE for a mean of 7.3 years, no statistically significant risk of VTE was found for patients with FVL (hazard ratio [HR]: 1.2, 95% confidence interval [CI]: 0.7‐1.9), PT20210 (HR: 0.7, 95% CI: 0.3‐2.0), or an anticoagulant (protein C, protein S or ATIII) deficiency (HR: 1.8, 95% CI: 0.9‐3.7).[15] Although unexplained VTE was statistically associated with VTE recurrence, heritable thrombophilia status was not.

In a systematic review and meta‐analysis investigating the association of FVL and PT20210 with recurrent VTE, Ho and colleagues found a statistically significant risk of recurrent VTE in patients with inherited thrombophilia due to FVL (odds ratio [OR]: 1.41, 95% CI: 1.14‐1.75) and PT20210 (OR: 1.72, 95% CI: 1.27‐2.31), and reported that at most, only up to 1 in 6 recurrent VTEs may be attributable to these mutations.[16] Based on this relatively modest effect, the authors question the utility of testing for inherited thrombophilia, as thrombophilia status is unlikely to warrant a change in type or duration of treatment.

Regardless of whether an underlying inherited thrombophilia is identified, patients with history of recurrent VTE are often candidates for long‐term anticoagulation. Testing for inherited thrombophilia in patients with prior VTE events will therefore not influence decisions regarding clinical management. Additionally, such testing may be confounded by ongoing disease or treatment (Table 1). For example, protein C, protein S antigen, and ATIII levels are low in the setting of acute VTE.[17, 18] Likewise, protein C and S (vitamin Kdependent proteins) will be low in the setting of anticoagulation with warfarin.[19] Moreover, ATIII activity and antigen levels are low in the setting of heparin use.[20] Lack of provider awareness regarding these interactions may have important negative consequences, including a spurious diagnosis of thrombophilia,[21, 22] unnecessary hematology consultation, and psychological distress to patients in the form of ongoing unwarranted testing or apprehension regarding recurrence.[23]

Limitations of Thrombophilia Workup in the Setting of Acute VTE or Anticoagulation
 Acute VTEAnticoagulation With WarfarinAnticoagulation With NOACsAnticoagulation With Heparin/LMWH
  • NOTE: Abbreviations: ATIII, antithrombin III deficiency; FVL, factor V Leiden gene mutation; LMWH, Low‐molecular‐weight heparin; MTHFR, methylenetetrahydrofolate reductase gene mutation; NOACs, novel oral anticoagulants (anti‐Xa or direct thrombin inhibitors); PT20210, prothrombin 20210 gene mutation; VTE, venous thromboembolism.*Deficiency in both protein and functional assays.

FVL/PT20210/MTHFR gene mutationsNo ImpactNo ImpactNo ImpactNo Impact
Protein C*DecreasedDecreasedNo impactNo impact
Protein S*DecreasedDecreasedNo impactNo impact
ATIII activityDecreasedSlight increaseSlight increaseDecreased
ATIII antigenDecreasedSlight increaseSlight increaseDecreased

Additionally, this expensive evaluation has estimated direct costs of $1100 to $2400 per thrombophilia panel based on estimation of charges billed by a large commercial laboratory.[24, 25] In 2014, over 280,000 claims were submitted under Medicare Part B across all care settings for a thrombophilia analysis including FVL, PT20210, and MTHFR gene mutations,[24] which would equate to between $300 million to $672 million.[26] Unfortunately, there have been no large‐scale trials to assess cost‐effectiveness. However, the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group stated that cost‐effectiveness modeling studies in this area require updating with current VTE risk estimates but are suggestive that routine FVL/PT20210 testing is not cost‐effective.[27]

ARE THERE CIRCUMSTANCES IN WHICH INPATIENT INHERITED THROMBOPHILIA TESTING PROVES BENEFICIAL?

The evidence for when to test for inherited thrombophilia is very limited and is often based on individualized risk. The current EGAPP guidelines acknowledge this limitation, specifically noting that there is a paucity of data evaluating management or prophylaxis of patients with homozygous or compound heterozygous FVL or P20210 mutation, and a lack of data surrounding whether or not knowledge of thrombophilia mutation should affect anticoagulation treatment.[27] This is why an individualized approach is deemed necessary. For example, the decision to prescribe hormone replacement therapy in women with a family history of inherited thrombophilia may be better informed by testing prior to treatment. Similarly, pregnant women with a family history or personal history of VTE may also benefit from inherited thrombophilia testing, as this may influence antepartum or postpartum management.[28, 29] The National Institute for Health and Clinical Excellence (NICE) guidelines recommend consideration of testing for hereditary thrombophilia in patients with unprovoked VTE and a first‐degree relative with VTE, if stopping anticoagulation treatment is planned; however, these recommendations are based solely on Guideline Development Group's experience and opinion.[30] Regardless, testing for inherited thrombophilia has significant potential consequences. Patients at risk should meet with an outpatient hematologist and/or a genetic counselor, if available, to determine the risks and benefits of testing.

WHAT DO GUIDELINES SAY ABOUT INHERITED THROMBOPHILIA TESTING?

The most recent NICE guidelines recommend against offering inherited thrombophilia testing to patients presenting with a provoked VTE in any clinical setting.[30] In patients diagnosed with unprovoked VTE, testing should not be considered unless a first degree relative with a history of VTE exists.[30] The NICE guidelines also recommend against routinely offering thrombophilia testing to asymptomatic first‐degree relatives of patients with a history of VTE or known inherited thrombophilia. This recommendation is reflected in the American Society of Hematology's Choosing Wisely recommendations since 2013.[31] Further, The American College of Medical Genetics and Genomics' Choosing Wisely recommendations from 2015 state that MTHFR mutations should never be included in any thrombophilia workup, as recent meta‐analyses have disproven an association between the presence of these variants and venous thromboembolism.[32]

The EGAPP Working Group recommends against routine testing for FVL or PT20210 in patients who present with an idiopathic VTE, as longer‐term anticoagulation offers similar benefits to patients with or without these mutations.[27] EGAPP also recommends against testing asymptomatic adult family members of patients with VTE and/or an FVL or PT20210 mutation for the purpose of considering primary prophylactic anticoagulation. In these circumstances, it is felt that the potential risks of thrombophilia testing outweigh any potential benefits.

HOW SHOULD HOSPITALISTS APPROACH TESTING OF INHERITED THROMBOPHILIA?

The providers in our case presentation are challenged with determining whether inpatient thrombophilia evaluation will add value to the evaluation of patients with unprovoked VTE. The available evidence suggests that clinicians should avoid ordering thrombophilia testing for hospitalized patients with unprovoked VTE because (1) many thrombophilia tests are inaccurate in the setting of acute VTE and/or anticoagulation, (2) results of testing often do not influence management, (3) testing is not cost‐effective, (4) a positive test result may lead to unnecessary patient anxiety, and (5) testing may result in inappropriately prolonged anticoagulation courses or unnecessary involvement of inpatient consultants. For these reasons, the patient in our case presentation should not be tested for inherited thrombophilia. In patients with personal or family histories of recurrent thromboembolism, modifiable clinical risk factors should be addressed, as these are more likely to influence treatment decisions compared to genetic testing. Finally, patients may be referred to an outpatient hematologist or geneticist for individualized discussions of risks and benefits of testing for inherited thrombophilia.

CONCLUSION

Inpatient evaluation for inherited thrombophilia for VTE is not clinically useful, cost‐effective, or reliable in the setting of VTE. The result of such testing does not affect management of acute primary or recurrent VTE. Testing should only be considered using an individualized approach in the outpatient setting with appropriate genetic counseling.

Disclosure: Christopher M. Petrilli, MD, and Lauren Heidemann, MD, contributed equally to this work. The authors report no conflicts of interest.

Do you think this is a low‐value practice? Is this truly a Thing We Do for No Reason? Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other Things We Do for No Reason topics by emailing TWDFNR@hospitalmedicine.org.

Files
References
  1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25‐year population‐based study. Arch Intern Med. 1998;158(6):585593.
  2. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326(19):12401245.
  3. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4:15.
  4. Lensing AW, Prandoni P, Prins MH, Buller HR. Deep‐vein thrombosis. Lancet. 1999;353(9151):479485.
  5. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):24502457.
  6. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e691Se736S.
  7. Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost. 2013;110(4):697705.
  8. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e195Se226S.
  9. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301(23):24722485.
  10. Cohn D, Vansenne F, Borgie C, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2009;(1):CD007069.
  11. Cohn DM, Vansenne F, Borgie CA, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2012;12:CD007069.
  12. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523526.
  13. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 2008;112(12):44324436.
  14. Merriman L, Greaves M. Testing for thrombophilia: an evidence‐based approach. Postgrad Med J. 2006;82(973):699704.
  15. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):23522361.
  16. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729736.
  17. Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest. 1986;77(2):416425.
  18. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14(6):12291239.
  19. Weiss P, Soff GA, Halkin H, Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res. 1987;45(6):783790.
  20. Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program. 2007:127135.
  21. Kadauke S, Khor B, Cott EM. Activated protein C resistance testing for factor V Leiden. Am J Hematol. 2014;89(12):11471150.
  22. Fair DS, Revak DJ. Quantitation of human protein S in the plasma of normal and warfarin‐treated individuals by radioimmunoassay. Thromb Res. 1984;36(6):527535.
  23. Bank I, Scavenius MP, Buller HR, Middeldorp S. Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res. 2004;113(1):712.
  24. Abramson N, Abramson S. Hypercoagulability: clinical assessment and treatment. South Med J. 2001;94(10):10131020.
  25. Somma J, Sussman II, Rand JH. An evaluation of thrombophilia screening in an urban tertiary care medical center: A “real world” experience. Am J Clin Pathol. 2006;126(1):120127.
  26. CodeMap. Available at: https://www.codemap.com. Accessed January 18, 2016.
  27. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. 2011;13(1):6776.
  28. Brill‐Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med. 2000;343(20):14391444.
  29. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy‐related venous thromboembolism in anticoagulant factor‐deficient women: implications for prophylaxis. Ann Intern Med. 1996;125(12):955960.
  30. Chong LY, Fenu E, Stansby G, Hodgkinson S; Guideline Development Group. Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. BMJ. 2012;344:e3979.
  31. American Society of Hematology. Ten things physicians and patients should question. Choosing Wisely website. Available at: http://www.choosingwisely.org/societies/american‐society‐of‐hematology. Published December 4, 2013. Accessed January 18, 2016.
  32. American College of Medical Genetics and Genomics. Five Things patients and providers should question. Choosing Wisely website. Available at: http://www.choosingwisely.org/societies/american‐college‐of‐medical‐genetics‐and‐genomics. Published July 10, 2015. Accessed March 13, 2016.
Article PDF
Issue
Journal of Hospital Medicine - 11(11)
Publications
Page Number
801-804
Sections
Files
Files
Article PDF
Article PDF

The Things We Do for No Reason (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent black and white conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Inherited thrombophilia refers to a genetic condition that predisposes to an increased risk of venous thromboembolism (VTE). This disorder is prevalent in approximately 7% of the population and includes mutations such as factor V Leiden, prothrombin 20210, protein C deficiency, protein S deficiency, antithrombin deficiency, and methylene tetrahydrofolate reductase. The relative risk of VTE is 3‐ to 20‐fold greater in patients with inherited thrombophilia compared with the general population. Is testing for inherited thrombophilia recommended? The available evidence suggests that testing for inherited thrombophilia is not recommended in most clinical settings. In patients without a personal history of VTE, thrombophilia results do not change management, as there is no evidence to support thromboprophylaxis in this setting. In patients with a personal history of provoked or unprovoked VTE, inpatient testing is not indicated, as results do not influence management, testing is not cost‐effective, and a positive test result may lead to unnecessary patient anxiety or may result in unnecessary involvement of consultants. Testing in hospitalized patients has even more limitations because many thrombophilia tests are inaccurate in the setting of acute VTE and/or anticoagulation.

CASE PRESENTATION

A 23‐year‐old man presents to the emergency room with pleuritic chest pain and new oxygen requirement of 2 L nasal cannula. He has a history of unprovoked lower extremity deep venous thrombosis (DVT) diagnosed at age 20 and completed 3 months of systemic anticoagulation without complications. He reports no family history of clotting disorders or venous thromboembolism (VTE) and no reversible risk factors for VTE such as prolonged immobility, recent surgery, or high‐risk medications. A computed tomogram pulmonary embolism protocol shows multiple right lower lobe, segmental pulmonary emboli. Anticoagulation is initiated, and the patient is admitted to the hospital. Will inpatient inherited thrombophilia testing impact management for this case?

WHY MAY INHERITED THROMBOPHILIA TESTING PROVE HELPFUL?

The annual incidence rate of a first VTE event is estimated as 117 per 100,000 individuals per year.[1] The most common presentations are symptomatic DVT of the leg (annual incidence approximately 48 per 100,000 people), or a pulmonary embolism (annual incidence approximately 69 per 100,000 people).[1] Pulmonary embolism results in death in up to 30% of untreated patients and 2.5% of patients who receive systemic anticoagulation.[2] Principal in the pathogenesis of VTE are factors described by Virchow's triad: venous stasis, endothelial injury, and systemic hypercoagulability. By identifying a mutation in 1 or more of the factors in the clotting pathway, an evaluation for inherited thrombophilia theoretically may unearth factors that drive systemic hypercoagulability and inform decision making so as to prevent future events.

Inherited thrombophilia refers to a genetic condition that predisposes to an increased risk of VTE.[3] Approximately 7% of the general population has inherited thrombophilia, which includes factor V Leiden (FVL) mutation, prothrombin 20210 mutation (PT20210), protein C deficiency, protein S deficiency, antithrombin III (ATIII) deficiency, and methylene tetrahydrofolate reductase mutation (MTHFR).[4] Of note, the definition does not include acquired etiologies, such as antiphospholipid antibody syndrome. Depending on the underlying condition and expression of the genetic abnormality, the relative risk of VTE in patients with inherited thrombophilia is 3‐ to 20‐fold greater than that of the general population.[5] Therefore, it is logical to consider that testing for inherited thrombophilia might be clinically useful. However, the evidence for doing so is very limited.

DOES INHERITED THROMBOPHILIA TESTING CHANGE MANAGEMENT?

An inherited thrombophilia evaluation is unlikely to affect management in most clinical settings. There is no current evidence to support primary prophylaxis[6] nor is there evidence that management of patients with recurrent VTE should be altered in the setting of inherited thrombophilia.

To date, no prospective trials have evaluated the efficacy of anticoagulant use for primary prevention of VTE in patients with inherited thrombophilia.[6] Given the limited evidence for thromboprophylaxis and risks of anticoagulation, primary prevention for patients with inherited thrombophilia that remain asymptomatic is not recommended by the current American College of Chest Physicians guidelines.[7, 8]

Similarly, in patients with a first VTE or recurrent VTE, diagnosis of inherited thrombophilia is often not associated with recurrent events, which suggests that other nongenetic factors may be just as important, if not more important, in determining the risk of recurrence.[9] Although no randomized controlled or controlled clinical trials have evaluated the effects of testing for inherited thrombophilia on recurrent VTE,[10, 11] several prospective studies have assessed risk factors for recurrence. Data from these studies suggest that recurrence rates after unprovoked VTE are only weakly correlated with inherited thrombophilia status.[12, 13] Rather, it is postulated that patients with recurrent VTE may exhibit a prothrombotic tendency regardless of underlying genetic predisposition. In this case, decisions regarding anticoagulation do not vary by thrombophilia status. Instead, thrombophilia testing may divert attention away from the management of more prevalent, potentially modifiable risk factors such as immobility, oral contraceptive use, or malignancy, all of which are associated with recurrent VTE.[14] These provoking factors are the most important determinants of the chance of VTE recurrence as well as the most significant factors to take into account when deciding duration of anticoagulation.

Christiansen et al. performed a prospective study evaluating the association between recurrent VTE and thrombophilia status. After following 474 patients with confirmed first episode VTE for a mean of 7.3 years, no statistically significant risk of VTE was found for patients with FVL (hazard ratio [HR]: 1.2, 95% confidence interval [CI]: 0.7‐1.9), PT20210 (HR: 0.7, 95% CI: 0.3‐2.0), or an anticoagulant (protein C, protein S or ATIII) deficiency (HR: 1.8, 95% CI: 0.9‐3.7).[15] Although unexplained VTE was statistically associated with VTE recurrence, heritable thrombophilia status was not.

In a systematic review and meta‐analysis investigating the association of FVL and PT20210 with recurrent VTE, Ho and colleagues found a statistically significant risk of recurrent VTE in patients with inherited thrombophilia due to FVL (odds ratio [OR]: 1.41, 95% CI: 1.14‐1.75) and PT20210 (OR: 1.72, 95% CI: 1.27‐2.31), and reported that at most, only up to 1 in 6 recurrent VTEs may be attributable to these mutations.[16] Based on this relatively modest effect, the authors question the utility of testing for inherited thrombophilia, as thrombophilia status is unlikely to warrant a change in type or duration of treatment.

Regardless of whether an underlying inherited thrombophilia is identified, patients with history of recurrent VTE are often candidates for long‐term anticoagulation. Testing for inherited thrombophilia in patients with prior VTE events will therefore not influence decisions regarding clinical management. Additionally, such testing may be confounded by ongoing disease or treatment (Table 1). For example, protein C, protein S antigen, and ATIII levels are low in the setting of acute VTE.[17, 18] Likewise, protein C and S (vitamin Kdependent proteins) will be low in the setting of anticoagulation with warfarin.[19] Moreover, ATIII activity and antigen levels are low in the setting of heparin use.[20] Lack of provider awareness regarding these interactions may have important negative consequences, including a spurious diagnosis of thrombophilia,[21, 22] unnecessary hematology consultation, and psychological distress to patients in the form of ongoing unwarranted testing or apprehension regarding recurrence.[23]

Limitations of Thrombophilia Workup in the Setting of Acute VTE or Anticoagulation
 Acute VTEAnticoagulation With WarfarinAnticoagulation With NOACsAnticoagulation With Heparin/LMWH
  • NOTE: Abbreviations: ATIII, antithrombin III deficiency; FVL, factor V Leiden gene mutation; LMWH, Low‐molecular‐weight heparin; MTHFR, methylenetetrahydrofolate reductase gene mutation; NOACs, novel oral anticoagulants (anti‐Xa or direct thrombin inhibitors); PT20210, prothrombin 20210 gene mutation; VTE, venous thromboembolism.*Deficiency in both protein and functional assays.

FVL/PT20210/MTHFR gene mutationsNo ImpactNo ImpactNo ImpactNo Impact
Protein C*DecreasedDecreasedNo impactNo impact
Protein S*DecreasedDecreasedNo impactNo impact
ATIII activityDecreasedSlight increaseSlight increaseDecreased
ATIII antigenDecreasedSlight increaseSlight increaseDecreased

Additionally, this expensive evaluation has estimated direct costs of $1100 to $2400 per thrombophilia panel based on estimation of charges billed by a large commercial laboratory.[24, 25] In 2014, over 280,000 claims were submitted under Medicare Part B across all care settings for a thrombophilia analysis including FVL, PT20210, and MTHFR gene mutations,[24] which would equate to between $300 million to $672 million.[26] Unfortunately, there have been no large‐scale trials to assess cost‐effectiveness. However, the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group stated that cost‐effectiveness modeling studies in this area require updating with current VTE risk estimates but are suggestive that routine FVL/PT20210 testing is not cost‐effective.[27]

ARE THERE CIRCUMSTANCES IN WHICH INPATIENT INHERITED THROMBOPHILIA TESTING PROVES BENEFICIAL?

The evidence for when to test for inherited thrombophilia is very limited and is often based on individualized risk. The current EGAPP guidelines acknowledge this limitation, specifically noting that there is a paucity of data evaluating management or prophylaxis of patients with homozygous or compound heterozygous FVL or P20210 mutation, and a lack of data surrounding whether or not knowledge of thrombophilia mutation should affect anticoagulation treatment.[27] This is why an individualized approach is deemed necessary. For example, the decision to prescribe hormone replacement therapy in women with a family history of inherited thrombophilia may be better informed by testing prior to treatment. Similarly, pregnant women with a family history or personal history of VTE may also benefit from inherited thrombophilia testing, as this may influence antepartum or postpartum management.[28, 29] The National Institute for Health and Clinical Excellence (NICE) guidelines recommend consideration of testing for hereditary thrombophilia in patients with unprovoked VTE and a first‐degree relative with VTE, if stopping anticoagulation treatment is planned; however, these recommendations are based solely on Guideline Development Group's experience and opinion.[30] Regardless, testing for inherited thrombophilia has significant potential consequences. Patients at risk should meet with an outpatient hematologist and/or a genetic counselor, if available, to determine the risks and benefits of testing.

WHAT DO GUIDELINES SAY ABOUT INHERITED THROMBOPHILIA TESTING?

The most recent NICE guidelines recommend against offering inherited thrombophilia testing to patients presenting with a provoked VTE in any clinical setting.[30] In patients diagnosed with unprovoked VTE, testing should not be considered unless a first degree relative with a history of VTE exists.[30] The NICE guidelines also recommend against routinely offering thrombophilia testing to asymptomatic first‐degree relatives of patients with a history of VTE or known inherited thrombophilia. This recommendation is reflected in the American Society of Hematology's Choosing Wisely recommendations since 2013.[31] Further, The American College of Medical Genetics and Genomics' Choosing Wisely recommendations from 2015 state that MTHFR mutations should never be included in any thrombophilia workup, as recent meta‐analyses have disproven an association between the presence of these variants and venous thromboembolism.[32]

The EGAPP Working Group recommends against routine testing for FVL or PT20210 in patients who present with an idiopathic VTE, as longer‐term anticoagulation offers similar benefits to patients with or without these mutations.[27] EGAPP also recommends against testing asymptomatic adult family members of patients with VTE and/or an FVL or PT20210 mutation for the purpose of considering primary prophylactic anticoagulation. In these circumstances, it is felt that the potential risks of thrombophilia testing outweigh any potential benefits.

HOW SHOULD HOSPITALISTS APPROACH TESTING OF INHERITED THROMBOPHILIA?

The providers in our case presentation are challenged with determining whether inpatient thrombophilia evaluation will add value to the evaluation of patients with unprovoked VTE. The available evidence suggests that clinicians should avoid ordering thrombophilia testing for hospitalized patients with unprovoked VTE because (1) many thrombophilia tests are inaccurate in the setting of acute VTE and/or anticoagulation, (2) results of testing often do not influence management, (3) testing is not cost‐effective, (4) a positive test result may lead to unnecessary patient anxiety, and (5) testing may result in inappropriately prolonged anticoagulation courses or unnecessary involvement of inpatient consultants. For these reasons, the patient in our case presentation should not be tested for inherited thrombophilia. In patients with personal or family histories of recurrent thromboembolism, modifiable clinical risk factors should be addressed, as these are more likely to influence treatment decisions compared to genetic testing. Finally, patients may be referred to an outpatient hematologist or geneticist for individualized discussions of risks and benefits of testing for inherited thrombophilia.

CONCLUSION

Inpatient evaluation for inherited thrombophilia for VTE is not clinically useful, cost‐effective, or reliable in the setting of VTE. The result of such testing does not affect management of acute primary or recurrent VTE. Testing should only be considered using an individualized approach in the outpatient setting with appropriate genetic counseling.

Disclosure: Christopher M. Petrilli, MD, and Lauren Heidemann, MD, contributed equally to this work. The authors report no conflicts of interest.

Do you think this is a low‐value practice? Is this truly a Thing We Do for No Reason? Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other Things We Do for No Reason topics by emailing TWDFNR@hospitalmedicine.org.

The Things We Do for No Reason (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent black and white conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Inherited thrombophilia refers to a genetic condition that predisposes to an increased risk of venous thromboembolism (VTE). This disorder is prevalent in approximately 7% of the population and includes mutations such as factor V Leiden, prothrombin 20210, protein C deficiency, protein S deficiency, antithrombin deficiency, and methylene tetrahydrofolate reductase. The relative risk of VTE is 3‐ to 20‐fold greater in patients with inherited thrombophilia compared with the general population. Is testing for inherited thrombophilia recommended? The available evidence suggests that testing for inherited thrombophilia is not recommended in most clinical settings. In patients without a personal history of VTE, thrombophilia results do not change management, as there is no evidence to support thromboprophylaxis in this setting. In patients with a personal history of provoked or unprovoked VTE, inpatient testing is not indicated, as results do not influence management, testing is not cost‐effective, and a positive test result may lead to unnecessary patient anxiety or may result in unnecessary involvement of consultants. Testing in hospitalized patients has even more limitations because many thrombophilia tests are inaccurate in the setting of acute VTE and/or anticoagulation.

CASE PRESENTATION

A 23‐year‐old man presents to the emergency room with pleuritic chest pain and new oxygen requirement of 2 L nasal cannula. He has a history of unprovoked lower extremity deep venous thrombosis (DVT) diagnosed at age 20 and completed 3 months of systemic anticoagulation without complications. He reports no family history of clotting disorders or venous thromboembolism (VTE) and no reversible risk factors for VTE such as prolonged immobility, recent surgery, or high‐risk medications. A computed tomogram pulmonary embolism protocol shows multiple right lower lobe, segmental pulmonary emboli. Anticoagulation is initiated, and the patient is admitted to the hospital. Will inpatient inherited thrombophilia testing impact management for this case?

WHY MAY INHERITED THROMBOPHILIA TESTING PROVE HELPFUL?

The annual incidence rate of a first VTE event is estimated as 117 per 100,000 individuals per year.[1] The most common presentations are symptomatic DVT of the leg (annual incidence approximately 48 per 100,000 people), or a pulmonary embolism (annual incidence approximately 69 per 100,000 people).[1] Pulmonary embolism results in death in up to 30% of untreated patients and 2.5% of patients who receive systemic anticoagulation.[2] Principal in the pathogenesis of VTE are factors described by Virchow's triad: venous stasis, endothelial injury, and systemic hypercoagulability. By identifying a mutation in 1 or more of the factors in the clotting pathway, an evaluation for inherited thrombophilia theoretically may unearth factors that drive systemic hypercoagulability and inform decision making so as to prevent future events.

Inherited thrombophilia refers to a genetic condition that predisposes to an increased risk of VTE.[3] Approximately 7% of the general population has inherited thrombophilia, which includes factor V Leiden (FVL) mutation, prothrombin 20210 mutation (PT20210), protein C deficiency, protein S deficiency, antithrombin III (ATIII) deficiency, and methylene tetrahydrofolate reductase mutation (MTHFR).[4] Of note, the definition does not include acquired etiologies, such as antiphospholipid antibody syndrome. Depending on the underlying condition and expression of the genetic abnormality, the relative risk of VTE in patients with inherited thrombophilia is 3‐ to 20‐fold greater than that of the general population.[5] Therefore, it is logical to consider that testing for inherited thrombophilia might be clinically useful. However, the evidence for doing so is very limited.

DOES INHERITED THROMBOPHILIA TESTING CHANGE MANAGEMENT?

An inherited thrombophilia evaluation is unlikely to affect management in most clinical settings. There is no current evidence to support primary prophylaxis[6] nor is there evidence that management of patients with recurrent VTE should be altered in the setting of inherited thrombophilia.

To date, no prospective trials have evaluated the efficacy of anticoagulant use for primary prevention of VTE in patients with inherited thrombophilia.[6] Given the limited evidence for thromboprophylaxis and risks of anticoagulation, primary prevention for patients with inherited thrombophilia that remain asymptomatic is not recommended by the current American College of Chest Physicians guidelines.[7, 8]

Similarly, in patients with a first VTE or recurrent VTE, diagnosis of inherited thrombophilia is often not associated with recurrent events, which suggests that other nongenetic factors may be just as important, if not more important, in determining the risk of recurrence.[9] Although no randomized controlled or controlled clinical trials have evaluated the effects of testing for inherited thrombophilia on recurrent VTE,[10, 11] several prospective studies have assessed risk factors for recurrence. Data from these studies suggest that recurrence rates after unprovoked VTE are only weakly correlated with inherited thrombophilia status.[12, 13] Rather, it is postulated that patients with recurrent VTE may exhibit a prothrombotic tendency regardless of underlying genetic predisposition. In this case, decisions regarding anticoagulation do not vary by thrombophilia status. Instead, thrombophilia testing may divert attention away from the management of more prevalent, potentially modifiable risk factors such as immobility, oral contraceptive use, or malignancy, all of which are associated with recurrent VTE.[14] These provoking factors are the most important determinants of the chance of VTE recurrence as well as the most significant factors to take into account when deciding duration of anticoagulation.

Christiansen et al. performed a prospective study evaluating the association between recurrent VTE and thrombophilia status. After following 474 patients with confirmed first episode VTE for a mean of 7.3 years, no statistically significant risk of VTE was found for patients with FVL (hazard ratio [HR]: 1.2, 95% confidence interval [CI]: 0.7‐1.9), PT20210 (HR: 0.7, 95% CI: 0.3‐2.0), or an anticoagulant (protein C, protein S or ATIII) deficiency (HR: 1.8, 95% CI: 0.9‐3.7).[15] Although unexplained VTE was statistically associated with VTE recurrence, heritable thrombophilia status was not.

In a systematic review and meta‐analysis investigating the association of FVL and PT20210 with recurrent VTE, Ho and colleagues found a statistically significant risk of recurrent VTE in patients with inherited thrombophilia due to FVL (odds ratio [OR]: 1.41, 95% CI: 1.14‐1.75) and PT20210 (OR: 1.72, 95% CI: 1.27‐2.31), and reported that at most, only up to 1 in 6 recurrent VTEs may be attributable to these mutations.[16] Based on this relatively modest effect, the authors question the utility of testing for inherited thrombophilia, as thrombophilia status is unlikely to warrant a change in type or duration of treatment.

Regardless of whether an underlying inherited thrombophilia is identified, patients with history of recurrent VTE are often candidates for long‐term anticoagulation. Testing for inherited thrombophilia in patients with prior VTE events will therefore not influence decisions regarding clinical management. Additionally, such testing may be confounded by ongoing disease or treatment (Table 1). For example, protein C, protein S antigen, and ATIII levels are low in the setting of acute VTE.[17, 18] Likewise, protein C and S (vitamin Kdependent proteins) will be low in the setting of anticoagulation with warfarin.[19] Moreover, ATIII activity and antigen levels are low in the setting of heparin use.[20] Lack of provider awareness regarding these interactions may have important negative consequences, including a spurious diagnosis of thrombophilia,[21, 22] unnecessary hematology consultation, and psychological distress to patients in the form of ongoing unwarranted testing or apprehension regarding recurrence.[23]

Limitations of Thrombophilia Workup in the Setting of Acute VTE or Anticoagulation
 Acute VTEAnticoagulation With WarfarinAnticoagulation With NOACsAnticoagulation With Heparin/LMWH
  • NOTE: Abbreviations: ATIII, antithrombin III deficiency; FVL, factor V Leiden gene mutation; LMWH, Low‐molecular‐weight heparin; MTHFR, methylenetetrahydrofolate reductase gene mutation; NOACs, novel oral anticoagulants (anti‐Xa or direct thrombin inhibitors); PT20210, prothrombin 20210 gene mutation; VTE, venous thromboembolism.*Deficiency in both protein and functional assays.

FVL/PT20210/MTHFR gene mutationsNo ImpactNo ImpactNo ImpactNo Impact
Protein C*DecreasedDecreasedNo impactNo impact
Protein S*DecreasedDecreasedNo impactNo impact
ATIII activityDecreasedSlight increaseSlight increaseDecreased
ATIII antigenDecreasedSlight increaseSlight increaseDecreased

Additionally, this expensive evaluation has estimated direct costs of $1100 to $2400 per thrombophilia panel based on estimation of charges billed by a large commercial laboratory.[24, 25] In 2014, over 280,000 claims were submitted under Medicare Part B across all care settings for a thrombophilia analysis including FVL, PT20210, and MTHFR gene mutations,[24] which would equate to between $300 million to $672 million.[26] Unfortunately, there have been no large‐scale trials to assess cost‐effectiveness. However, the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group stated that cost‐effectiveness modeling studies in this area require updating with current VTE risk estimates but are suggestive that routine FVL/PT20210 testing is not cost‐effective.[27]

ARE THERE CIRCUMSTANCES IN WHICH INPATIENT INHERITED THROMBOPHILIA TESTING PROVES BENEFICIAL?

The evidence for when to test for inherited thrombophilia is very limited and is often based on individualized risk. The current EGAPP guidelines acknowledge this limitation, specifically noting that there is a paucity of data evaluating management or prophylaxis of patients with homozygous or compound heterozygous FVL or P20210 mutation, and a lack of data surrounding whether or not knowledge of thrombophilia mutation should affect anticoagulation treatment.[27] This is why an individualized approach is deemed necessary. For example, the decision to prescribe hormone replacement therapy in women with a family history of inherited thrombophilia may be better informed by testing prior to treatment. Similarly, pregnant women with a family history or personal history of VTE may also benefit from inherited thrombophilia testing, as this may influence antepartum or postpartum management.[28, 29] The National Institute for Health and Clinical Excellence (NICE) guidelines recommend consideration of testing for hereditary thrombophilia in patients with unprovoked VTE and a first‐degree relative with VTE, if stopping anticoagulation treatment is planned; however, these recommendations are based solely on Guideline Development Group's experience and opinion.[30] Regardless, testing for inherited thrombophilia has significant potential consequences. Patients at risk should meet with an outpatient hematologist and/or a genetic counselor, if available, to determine the risks and benefits of testing.

WHAT DO GUIDELINES SAY ABOUT INHERITED THROMBOPHILIA TESTING?

The most recent NICE guidelines recommend against offering inherited thrombophilia testing to patients presenting with a provoked VTE in any clinical setting.[30] In patients diagnosed with unprovoked VTE, testing should not be considered unless a first degree relative with a history of VTE exists.[30] The NICE guidelines also recommend against routinely offering thrombophilia testing to asymptomatic first‐degree relatives of patients with a history of VTE or known inherited thrombophilia. This recommendation is reflected in the American Society of Hematology's Choosing Wisely recommendations since 2013.[31] Further, The American College of Medical Genetics and Genomics' Choosing Wisely recommendations from 2015 state that MTHFR mutations should never be included in any thrombophilia workup, as recent meta‐analyses have disproven an association between the presence of these variants and venous thromboembolism.[32]

The EGAPP Working Group recommends against routine testing for FVL or PT20210 in patients who present with an idiopathic VTE, as longer‐term anticoagulation offers similar benefits to patients with or without these mutations.[27] EGAPP also recommends against testing asymptomatic adult family members of patients with VTE and/or an FVL or PT20210 mutation for the purpose of considering primary prophylactic anticoagulation. In these circumstances, it is felt that the potential risks of thrombophilia testing outweigh any potential benefits.

HOW SHOULD HOSPITALISTS APPROACH TESTING OF INHERITED THROMBOPHILIA?

The providers in our case presentation are challenged with determining whether inpatient thrombophilia evaluation will add value to the evaluation of patients with unprovoked VTE. The available evidence suggests that clinicians should avoid ordering thrombophilia testing for hospitalized patients with unprovoked VTE because (1) many thrombophilia tests are inaccurate in the setting of acute VTE and/or anticoagulation, (2) results of testing often do not influence management, (3) testing is not cost‐effective, (4) a positive test result may lead to unnecessary patient anxiety, and (5) testing may result in inappropriately prolonged anticoagulation courses or unnecessary involvement of inpatient consultants. For these reasons, the patient in our case presentation should not be tested for inherited thrombophilia. In patients with personal or family histories of recurrent thromboembolism, modifiable clinical risk factors should be addressed, as these are more likely to influence treatment decisions compared to genetic testing. Finally, patients may be referred to an outpatient hematologist or geneticist for individualized discussions of risks and benefits of testing for inherited thrombophilia.

CONCLUSION

Inpatient evaluation for inherited thrombophilia for VTE is not clinically useful, cost‐effective, or reliable in the setting of VTE. The result of such testing does not affect management of acute primary or recurrent VTE. Testing should only be considered using an individualized approach in the outpatient setting with appropriate genetic counseling.

Disclosure: Christopher M. Petrilli, MD, and Lauren Heidemann, MD, contributed equally to this work. The authors report no conflicts of interest.

Do you think this is a low‐value practice? Is this truly a Thing We Do for No Reason? Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other Things We Do for No Reason topics by emailing TWDFNR@hospitalmedicine.org.

References
  1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25‐year population‐based study. Arch Intern Med. 1998;158(6):585593.
  2. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326(19):12401245.
  3. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4:15.
  4. Lensing AW, Prandoni P, Prins MH, Buller HR. Deep‐vein thrombosis. Lancet. 1999;353(9151):479485.
  5. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):24502457.
  6. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e691Se736S.
  7. Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost. 2013;110(4):697705.
  8. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e195Se226S.
  9. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301(23):24722485.
  10. Cohn D, Vansenne F, Borgie C, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2009;(1):CD007069.
  11. Cohn DM, Vansenne F, Borgie CA, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2012;12:CD007069.
  12. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523526.
  13. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 2008;112(12):44324436.
  14. Merriman L, Greaves M. Testing for thrombophilia: an evidence‐based approach. Postgrad Med J. 2006;82(973):699704.
  15. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):23522361.
  16. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729736.
  17. Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest. 1986;77(2):416425.
  18. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14(6):12291239.
  19. Weiss P, Soff GA, Halkin H, Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res. 1987;45(6):783790.
  20. Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program. 2007:127135.
  21. Kadauke S, Khor B, Cott EM. Activated protein C resistance testing for factor V Leiden. Am J Hematol. 2014;89(12):11471150.
  22. Fair DS, Revak DJ. Quantitation of human protein S in the plasma of normal and warfarin‐treated individuals by radioimmunoassay. Thromb Res. 1984;36(6):527535.
  23. Bank I, Scavenius MP, Buller HR, Middeldorp S. Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res. 2004;113(1):712.
  24. Abramson N, Abramson S. Hypercoagulability: clinical assessment and treatment. South Med J. 2001;94(10):10131020.
  25. Somma J, Sussman II, Rand JH. An evaluation of thrombophilia screening in an urban tertiary care medical center: A “real world” experience. Am J Clin Pathol. 2006;126(1):120127.
  26. CodeMap. Available at: https://www.codemap.com. Accessed January 18, 2016.
  27. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. 2011;13(1):6776.
  28. Brill‐Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med. 2000;343(20):14391444.
  29. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy‐related venous thromboembolism in anticoagulant factor‐deficient women: implications for prophylaxis. Ann Intern Med. 1996;125(12):955960.
  30. Chong LY, Fenu E, Stansby G, Hodgkinson S; Guideline Development Group. Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. BMJ. 2012;344:e3979.
  31. American Society of Hematology. Ten things physicians and patients should question. Choosing Wisely website. Available at: http://www.choosingwisely.org/societies/american‐society‐of‐hematology. Published December 4, 2013. Accessed January 18, 2016.
  32. American College of Medical Genetics and Genomics. Five Things patients and providers should question. Choosing Wisely website. Available at: http://www.choosingwisely.org/societies/american‐college‐of‐medical‐genetics‐and‐genomics. Published July 10, 2015. Accessed March 13, 2016.
References
  1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25‐year population‐based study. Arch Intern Med. 1998;158(6):585593.
  2. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326(19):12401245.
  3. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4:15.
  4. Lensing AW, Prandoni P, Prins MH, Buller HR. Deep‐vein thrombosis. Lancet. 1999;353(9151):479485.
  5. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):24502457.
  6. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e691Se736S.
  7. Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost. 2013;110(4):697705.
  8. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e195Se226S.
  9. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301(23):24722485.
  10. Cohn D, Vansenne F, Borgie C, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2009;(1):CD007069.
  11. Cohn DM, Vansenne F, Borgie CA, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2012;12:CD007069.
  12. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523526.
  13. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 2008;112(12):44324436.
  14. Merriman L, Greaves M. Testing for thrombophilia: an evidence‐based approach. Postgrad Med J. 2006;82(973):699704.
  15. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):23522361.
  16. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729736.
  17. Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest. 1986;77(2):416425.
  18. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14(6):12291239.
  19. Weiss P, Soff GA, Halkin H, Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res. 1987;45(6):783790.
  20. Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program. 2007:127135.
  21. Kadauke S, Khor B, Cott EM. Activated protein C resistance testing for factor V Leiden. Am J Hematol. 2014;89(12):11471150.
  22. Fair DS, Revak DJ. Quantitation of human protein S in the plasma of normal and warfarin‐treated individuals by radioimmunoassay. Thromb Res. 1984;36(6):527535.
  23. Bank I, Scavenius MP, Buller HR, Middeldorp S. Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res. 2004;113(1):712.
  24. Abramson N, Abramson S. Hypercoagulability: clinical assessment and treatment. South Med J. 2001;94(10):10131020.
  25. Somma J, Sussman II, Rand JH. An evaluation of thrombophilia screening in an urban tertiary care medical center: A “real world” experience. Am J Clin Pathol. 2006;126(1):120127.
  26. CodeMap. Available at: https://www.codemap.com. Accessed January 18, 2016.
  27. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. 2011;13(1):6776.
  28. Brill‐Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med. 2000;343(20):14391444.
  29. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy‐related venous thromboembolism in anticoagulant factor‐deficient women: implications for prophylaxis. Ann Intern Med. 1996;125(12):955960.
  30. Chong LY, Fenu E, Stansby G, Hodgkinson S; Guideline Development Group. Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. BMJ. 2012;344:e3979.
  31. American Society of Hematology. Ten things physicians and patients should question. Choosing Wisely website. Available at: http://www.choosingwisely.org/societies/american‐society‐of‐hematology. Published December 4, 2013. Accessed January 18, 2016.
  32. American College of Medical Genetics and Genomics. Five Things patients and providers should question. Choosing Wisely website. Available at: http://www.choosingwisely.org/societies/american‐college‐of‐medical‐genetics‐and‐genomics. Published July 10, 2015. Accessed March 13, 2016.
Issue
Journal of Hospital Medicine - 11(11)
Issue
Journal of Hospital Medicine - 11(11)
Page Number
801-804
Page Number
801-804
Publications
Publications
Article Type
Display Headline
Inpatient inherited thrombophilia testing
Display Headline
Inpatient inherited thrombophilia testing
Sections
Article Source

© 2016 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Christopher Petrilli, MD, 1500 East Medical Center Drive, Ann Arbor, MI 48109; Telephone: 734‐936‐4385; Fax: 877‐992‐3793; E‐mail: cpetrill@umich.edu
Content Gating
Open Access (article Unlocked/Open Access)
Alternative CME
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media
Media Files